WO2012136930A2 - Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation - Google Patents

Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation Download PDF

Info

Publication number
WO2012136930A2
WO2012136930A2 PCT/FR2012/050723 FR2012050723W WO2012136930A2 WO 2012136930 A2 WO2012136930 A2 WO 2012136930A2 FR 2012050723 W FR2012050723 W FR 2012050723W WO 2012136930 A2 WO2012136930 A2 WO 2012136930A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
chaulmoogra
tribulus terrestris
oil
extract
Prior art date
Application number
PCT/FR2012/050723
Other languages
French (fr)
Other versions
WO2012136930A3 (en
Inventor
Nadine Leconte
Jacques Leclere
Original Assignee
Laboratoire Nuxe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Nuxe filed Critical Laboratoire Nuxe
Priority to EP12718295.4A priority Critical patent/EP2694028A2/en
Publication of WO2012136930A2 publication Critical patent/WO2012136930A2/en
Publication of WO2012136930A3 publication Critical patent/WO2012136930A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin

Definitions

  • the present invention relates to a new composition based on chaulmoogra oil and Tribulus terrestris used in cosmetics, more particularly for the pigmentation of the skin.
  • the skin consists of superficial layers, namely the epidermis, and deeper layers, the dermis and hypodermis, and each has specific properties allowing the whole to react and adapt to the conditions of its environment.
  • the epidermis which is composed of three types of cells, namely keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, constitutes the outer layer and plays a role. fundamental to ensure the protection and maintenance of good trophicity.
  • the dermis serves as a support for the epidermis and is mainly composed of fibroblasts and an essential extracellular matrix ⁇ lement based on collagen and elastin.
  • Collagen fibers contribute to the texture and tone of the skin and elastin is responsible for its elasticity.
  • Other cells such as macrophages and leucocytes, are also present in the dermis layer.
  • the hypodermis which is the deepest layer of the skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects the muscles, bones, and internal organs from shock.
  • the pigmentation of the skin results from the presence of melanin in the epidermis and the dermis.
  • Melanin is a pigment produced by melanocytes located mainly in the basal layer, in the presence of tyrosinase (or monophenol monooxygenase), a cuproprotein enzyme that catalyzes the transformation of L-tyrosine into L-dihydroxyphenylalanine (L- dopa) which is then oxidized to dopaquinone, then
  • patent application FR 2 851 916 describes the use of catechol polyphenols in order to promote the natural pigmentation of the skin, and for example cocoa extracts that can be used in compositions for oral administration. of the xanthine extracts can be used in cosmetic and dermatological composi ⁇ tions to promote pigmentation of the skin, such as those obtained from cocoa beans described in FR 2654935.
  • Chaulmoogra oil has long been used in traditional medicine in Asia, particularly in India and China, for the treatment of leprosy, before the emergence of sulfonated drugs, including diaminodiphenylsulfone, and anti-tuberculosis antibiotics. such as rifampicin and rifamycin.
  • Hydnocarpic acid one of the main constituents of chaulmoogra oil, has been shown to exhibit antimycobacterial activity by inhibiting the growth of certain mycobacteria, such as Mycobacterium leprae, as indicated by PL Jacobsen and L. Levy, Antimycobacterial Agents and Chemotherapy (1973) pp. 373-379.
  • Patent FR 2,706,304 describes the use of chaulmoogra oil as a component of cosmetic compositions intended to harmonize the pigmentation of the skin, thanks to the pigmentation effects of the achromic cutaneous zones, that is to say little or no pigmented areas. , by migration of pigmentation from pigmented areas.
  • Patent FR 2,518,402 describes a composition containing chaulmoogra oil that can be used in cosmetics for the normalization of sebaceous secretions and cutaneous microbial flora.
  • FR 2,876,908 shows that chaulmoogra oils also have lipolytic effects useful in compositions intended for the treatment of fat overloads.
  • Chaulmoogra oils are mainly obtained by extracting the seeds of woody plants of the family Flacourtiaceae, growing in tropical regions, including a tree species Hydnocarpus wightiana and Taraktogenos soii. These plants are mainly Asian ori ⁇ gine, including India, Vietnam and Philippines, as well as Central and South America, including Brazil.
  • the seeds from which the chaulmoogra oils are extracted contain a high proportion of lipids, between 30 and 50% depending on the species, 15 to 20% of proteins and 4 to 6% of mineral matter, as well as 1 to 3% of 'unsaponifiables, glycerides of unsaturated fatty acids to pentenoic cycle, consti ⁇ essentially killed by chaulmoogric acid, hydnocarpic acid and gorlique acid. It seems that these acids are responsible for the therapeutic antimycobacterial action in the traditional treatment of leprosy. It has been observed that the spatial structure of these acids is similar to the cyclopentanoperhydroxyphenantrene ring characteristic of sterols.
  • the acids chaulmoogric, hydnocarpic and gorlic can be represented by the following general formulas, respectively:
  • These three acids include the same pentenoic cycloaliphatic ring having an acid group at the end of a carbon chain - (CH2) n _ wherein n is 10 in the case of acid hydno ⁇ carpique and 12 in the case of chaulmoogric acid, this same chain having a double bond in the case of gorlic acid.
  • the contents of each of these three acids in chaulmoogra oils vary according to the origin of the species. Chaulmoogra oils also contain fatty acids such as palmitic, oleic, palmitoleic, stearic, myristic, and traces of alepric and aleprylic acid.
  • Tribulus terrestris (terrestrial tribulus) is a plant of the zygophyllaceae family. It is a creeping little branched herb with a small yellow flower and very spiny fruit, a native species in southern France that is widespread in the arid and uncultivated regions of Africa and Asia. It contains one essence, steroidal saponosides whose genin may be diosgenin and trigogenin. Consumed as it is, it causes intoxication in sheep by clogging of the hepatic ducts as reported by R. R. Aslani et al., Vet. Res. Common. 27, 53-62 (2003). It is sometimes used as a sexual stimulant, and tests on the mouse, in oral administration, have shown an increase in testosterone and sperm volume, as indicated for example by K. Gauthaman, Phytomedicine, 15, 44-54 ( 2008).
  • the patent CN 101406511 describes a topical composition combining several substances of vegetable origin and in particular extracts of fruit of Malaytea scurfpea, fruit of Cnidium, Chaulmoogra and Tribulus terrestris or Astragalus complanatus, as well as metal derivatives (litharge and chloride mercureux), in substantially equivalent amounts, and this composition could be useful for the treatment of vitiligo.
  • KR 20090056778 discloses compositions of asso ⁇ ting medicinal herbs, in particular Hydnocarpi semen, Sesamum indicum, Dictamni radicis cortex, Mormodicae semen and Tribulus terrestris in substantially equal proportions, for the treatment of skin allergies, in particular atopic dermatitis and allergies to insect bites and drugs.
  • the studies carried out by the applicant on human melanocytes and reconstituted epidermis have shown that tribulus terrestris, used topically in the form of hydroglycolic extracts, has significant but weak depigmenting effects.
  • the subject of the present invention is therefore a new cosmetic composition combining chaulmoogra oil and / or its components and an extract of Tribulus terrestris, in appropriate concentrations, and more particularly in a weight ratio extracted from Tribulus terrestris / chaulmoogra oil. from 1: 1,000 to 1: 5, for the treatment of depigmented or unpigmented areas of the skin.
  • the invention also relates to the use of chaulmoogra oil, or its essential components such as chaulmoogric, hydnocarpic and gorlic acids, as well as their salts and esters, and extracts of Tribulus terrestris for the preparation of a cosmetic composition for the treatment of depigmented or non-pigmented areas of the skin.
  • chaulmoogra oil or its essential components such as chaulmoogric, hydnocarpic and gorlic acids, as well as their salts and esters, and extracts of Tribulus terrestris for the preparation of a cosmetic composition for the treatment of depigmented or non-pigmented areas of the skin.
  • the subject of the invention is also the use in cosmetics of the combination of an extract of Tribulus terrestris and of chaulmoogra oil in a weight ratio Tribulus terrestris / chaulmoogra oil of between 1: 1,000 and 1: 5, for the pigmentation of the skin.
  • the invention further relates to a non-therapeutic cosmetic treatment process for the skin, more particuliè ⁇ surely repigment for non-pigmented areas or dépigmen- Tees skin by applying a composition based on of Chaulmoogra oil and Tribulus terrestris extract in appropriate concentration on the area of the skin requiring such treatment.
  • the components of the chaulmoogra oil are preferably the chaulmoogric, hydnocarpic and gorlic acids and their salts and esters, which may be chosen from methyl, ethyl or benzyl esters, as well as sodium or potassium.
  • the salts or esters of chaulmoogric, hydropyric and gorlic acids may be chosen from methyl, ethyl or benzyl esters, as well as sodium or potassium salts, and for example sodium or potassium chaulmoograte and Sodium hydnocarpate.
  • the pigmenting activity of chaulmoogra oil is mainly due to the chaulmoogric, hydnocarpic and gorlic acids it contains, and the experiments carried out have shown that the association with an extract of Tribulus terrestris unexpectedly provides an improvement in this activity. known from Chaulmoogra whereas Tribulus, used alone, has a depigmenting action.
  • the chaulmoogra oils used in the present invention can be extracted from the seeds of plants of varieties such as Hydnocarpus wightiana, Taraktogenos soii, Hydnocarpus alpina, Hydnocarpus anthelmintica, Hydnocarpus cauliflora, Hydnocarpus dawnensis, Hydnocarpus heterophylla, Hydnocarpus hutchinsonii, Hydnocarpus ovoidea, Hydnocarpus subfalcata, Hydnocarpus venenata, Hydnocarpus verrucosa, Hydnocarpus woodii, Hydnocarpus calvipetala, Hydnocarpus ilicifolia, Hydnocarpus octandra, Gynocardia odorata, Oncoba echinata, Caloncoba glauca, Caloncoba welwitschii, Carpotroche brasiliensis, Carpotroche amazonica, As
  • Extracts of Tribulus terrestris are prepared from dried plants, the extract may represent from 1 to 20% of the total weight of the plant.
  • hydroalcoholic extracts may be prepared, for example, by way of the usual techniques, more particularly hydroglycolic or hydroethanolic extracts, or even hydroglycerinated extracts.
  • the extraction can be done for example by percolation or maceration at 100 g of plant per 500 g of water.
  • the cake is expressed and the liquors combined and supplemented to 500 g by addition of glycol such as butylene glycol and propylene glycol.
  • the extracts of Tribulus terrestris used in the compositions according to the present invention are preferably in the form of hydroglycolic extracts, for example in butylene glycol, of the whole plant dried and reduced to powder or, preferably, seeds or fruits dried and reduced to powder.
  • the extract that can be used in the composition of the invention is obtained from the dried and powdered fruits, which are macerated in a mixture of glycol and water, for example a mixture of 50/50 of glycol and water, followed by decantation, clarification, if necessary, and filtration. Clarification is usually by centrifugation or addition of a microparticle-absorbing substance, such as cellulose, polyvinyl pyrrolidone or absorbing soil.
  • the glycol may be chosen from butylene glycol-1,3, butylene glycol-1,4, and dipropylene glycol, and butylene glycol is preferably used.
  • the hydroglycolic extract of Tribulus terrestris used in the present invention is in the form of an amber-yellow liquid of characteristic odor, soluble in water and in alcohol, characterized by:
  • the ratio by weight of the tribulus terrestris extract to the oil of chaulograogra is between 1: 1,000 and 1: 5 and preferably between 1: 200 and 1:20.
  • the extract content of Tribulus terrestris may be between 0.01 and 0.5%, and preferably between 0.05 and 0.2% by weight relative to the total weight of the composition, while the content in oil of chaulmoogra, or in acids or salts or esters is generally between 0.1 and 20%, and preferably between 2 and 10% relative to the total weight of the composition, to provide the best pigmenting effects.
  • Chaulmoogra oil, and its acids or esters can be used advantageously in a form encapsulated in liposomes.
  • the liposomes are constituted by small hollow spheres, generally less than 500 nm in diameter, whose wall is formed of a double layer of lipids such as glucolipids or phospholipids . They can be obtained for example by ultrasonic treatment of a mixture of an aqueous solute and lipids. Lipids (phospholipids or glucolipids) are reorganized in a configuration where the energy of the whole is minimal, therefore thermodynamically the most stable. Liposomes are used in the cosmetics industry to deliver compounds into cells when the vesicle fuses with the plasma membrane.
  • At least part of the chaulmoogra oil is encapsulated in liposome-type vesicles.
  • compositions according to the present invention are preferably topically administrable.
  • topical administration refers to any method of applying the substance or composition directly to the skin on the area requiring treatment.
  • the composition can be administered topically may advantageously contain, in addition to the basic components described above, one or more other substances known to exert beneficial complementary effects for the skin, and more particu ⁇ larly tocopherol, vitamin A (retinol), retinoic acid, bactericidal agents, theophylline, monomethylsilanol, proline, or shea butter, as well as plant extracts such as Camellia japonica. It is also possible to the composition extracts or compounds known to facilitate the penetration of the active ingredients of the composition through the epidermis, for example ethoxydiglycol and saponosides of the hederagenin type.
  • compositions in accordance with the present invention are preferably intended for topical administration, and therefore contain carriers and excipients commonly used in compositions of this type, such as O / W or W / O emulsions, creams, gels or lotions.
  • the fatty phase may represent between 10 and 60% of the weight of the composition, the aqueous phase between 10 and 80% and the emulsifier between 2 and 20%, the remainder being constituted by the components above and the other components listed below.
  • the composition may also contain various substances and excipients chosen according to their known properties and the intended dosage form.
  • preservatives emulsifiers, viscosifiers, thickeners, gelling agents, antioxidants, moisturizers, surfactants, perfumes, oils, lipids, a specific solvent and the like can be incorporated into the composition. only water and various additives to improve the physical properties of the composition.
  • the emulsifier may be selected from high molecular weight carboxyvinyl polymers (e.g.
  • polysorbates eg Tween 60 or
  • sorbitan esters and in particular a monostearate such as Span 60® , a tristearate, a monopalmitate, and a sorbitan laurate. It is also possible to use other emulsifying agents such as various stearic or palmitic acid derivatives, and for example stearate of
  • PEG 100® mono- or diglycerides of stearic or palmitic acid, self-emulsifiable propylene glycol stearate, or polyglyceryl-2-sesquioleate, 1-ether polyoxyethylene cetyl, a siloxane polyglucoside, or an emulsifiable silicone.
  • Nonionic emulsifying mixtures such as Protegin X may also be used.
  • the viscosifying agents used in the compositions of the invention may be chosen from various polymers of acrylic acid, a copolymer of acrylate and acryloyl laurate, a cellulose gum, a silica, carboxyvinyl polymers, an aluminum silicate and magnesium, and it is possible to use, for example, the colloidal silica sold under the trademark Aerosil 200 or a crosslinked polyacrylic acid such as Carbopol 940.
  • the gelling agents or thickeners may be chosen for example from polyacrylamides, acrylates such as Pemulen®, cellulose derivatives such as hydroxypropyl cellulose, or natural gums.
  • the moisturizing agents used may be chosen for example from a polyol, sorbitol, maltitol, pentaerythritol, glyceryl polyacrylates and polymethacrylates, glycerol or glycerol derivatives. It is also possible to add emollients such as alkyl malate, isohexadecane, capric or caprylic acid triglycerides and the like.
  • preservatives of the technique of dermatological or cosmetological compositions can be used in the invention, and for example benzoic acid and an alkyl p-hydroxybenzoate such as methyl p-hydroxy-benzoate (Methylparaben), an alcohol such as phenoxyethanol or chlorphenesin or imidazolidinyl urea.
  • benzoic acid and an alkyl p-hydroxybenzoate such as methyl p-hydroxy-benzoate (Methylparaben)
  • an alcohol such as phenoxyethanol or chlorphenesin or imidazolidinyl urea.
  • the constituents of the fatty phase can be chosen from jojoba oil, corn oil, liquid petroleum jelly, sweet almond oil, hydrogenated coconut oil, safflower oil, saturated fatty acid glycerides, stearic acid, palmitic acid, octyl stearate, glyceryl palmitate, octyl palmitate, triglyceride caprylic and caprylic acids, 2-octyl-dodecanol, polyethylene glycol, 2-ethyl hexyl adipate, or silicone oils such as methyl phenyl polysiloxane, dimethicone, cyclomethicone and phenyl dimethicone .
  • the composition may also contain a solvent selected depending on the components used and the adminis tration form ⁇ envisaged.
  • the solvent may be, for example, water, and preferably demineralized water, or a specific solvent such as propylene glycol, a diethylene glycol ether, or an alcohol such as ethanol.
  • Ultraviolet protection agents may also advantageously be incorporated in the compositions, and for example hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from benzophenone or a benzophenone derivative such as 2-hydroxybenzophenone.
  • hydrophilic or lipophilic UV-A and UV-B sunscreens chosen from benzophenone or a benzophenone derivative such as 2-hydroxybenzophenone.
  • 4-methoxybenzophenone (Eusolex® 4360), or a cinnamic acid ester and more particularly octyl methoxycinnamate (Eusolex® 2292), ethyl-2-hexyl methoxycinnamate (Parsol MCX®), or a cyano- ⁇ , ⁇ -diphenylacrylate such as octo-crylene (Eusolex® OCR), 4-methylbenzylidene camphor (Eusolex 6300®), and dibenzoylmethane derivatives such as 4-is
  • the pH of the composition is preferably between 5.3 and 7.5, and may be adjusted, depending on the compositions, by the addition of an acid such as citric acid or a base such as sodium or potassium.
  • composition according to the present invention may be presented in the forms conventionally used for topical application, that is to say in the form of gel, lotion, emulsion (in particular cream or milk), transdermal patches. mask or ointment containing compatible and pharmaceutically acceptable excipients and carriers.
  • These forms of topical administration are prepared by the known techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion.
  • creams it is preferred to use lamellar structure emulsions containing little or no ethoxylated products.
  • the chaulmoogra oil is preferably preheated before being incorporated into the fatty phase, while the Tribulus terrestris extract used in combination is introduced into the aqueous or alcoholic phase.
  • topical compositions in accordance with the invention in the form of creams, milks or gels, which can be used in one or more daily applications, the duration of the treatment being generally of the order of one to four. three months.
  • compositions given below illustrate the invention without limiting its scope. Unless otherwise indicated, parts and percentages are by weight.
  • aqueous phase A is heated to 70-75 ° C while the fat phase B is heated to about 75 ° C, and then the two phases are thoroughly mixed with stirring.
  • Phase C after homogenization, is added to the mixture at a temperature of about 35 ° C. The whole is mixed and gradually cooled.
  • This anti stretch mark cream is used topically, once to twice a day on the areas of the skin to be treated, for a period of 1 to 3 months depending on the importance of the depigmentation to be treated.
  • the first significant effects can be observed as of the end of the 4th week, in the form of an attenuation of the contrast between depigmented zone and normally pigmented zone and these repigmenting effects are amplified in the continuation of the treatment.
  • a sunscreen based on chaulmoogra oil and Tribulus terrestris extract having the composition indicated below is prepared according to the usual techniques:
  • Fat phase A is heated with stirring to about 75 ° C and fat phase B is added thereto and then aqueous phase C at about 75 ° C, and the three phases are thoroughly mixed. with stirring. Finally, phase D is added and the mixture is then mixed and cooled progressively.
  • This cream can be used per application on the depigmented areas of the skin to be treated, once or twice a day, for a period of one to three months. Positive results are observed in some cases, especially when treating an area affected by vitiligo, from the end of the 4th week of application. If the treatment is stopped after 1 month, there is a regression of the general pigmentation but the repigmented areas remain acquired.
  • the cytotoxicity of the combination of Tribulus terrestris extract and chaulmoogra oil was evaluated by studying human melanocytes in culture, as follows.
  • keratinocytes of human origin are seeded on polycarbonate filters of 0.5 cm 2 in a defined medium (modified MCDB 153) and supplemented.
  • the cells are cultured for 14 days at the air / liquid interface, the culture medium being changed every two days.
  • the thus formed epidermis (SKINETIC®) are used for the study from the i4 th day of culture.
  • Human melanocytes were established from human skin (Clonetics) and amplified in MGM medium (Melanocytes Growth Medium, Clonetics). The tests were carried out on melanocytes between the 2 nd and 4 th passage to ensure reproducibility between different experiments.
  • Cytotoxicity was assessed for co-culture human melanocytes / reconstructed epidermis, for deter ⁇ mination of cell viability by the reduction of formazan blue test (MTT).
  • the melanocytes were distributed in 24-well plates at a rate of 2 ⁇ 10 5 cells per well in 0.5 ml of culture medium for 12 hours. The treated and untreated epidermis was then deposited in the wells containing the melanocytes in culture.
  • the test was conducted after 24 hours of contact between the studied product and the reconstituted melanocyte / epidermal co-culture.
  • Lot 1 negative control co-culture receiving no product.
  • Lot 2 co-cultivation treated by the combination of chaulmoogra oil (5%) / Tribulus terrestris (0.1%).
  • the viability of melanocytes is evaluated as follows.
  • MTT test Formazan blue reduction test
  • the cells are then lysed and the Formazan blue crystals are dissolved with 200 ⁇ l of dimethylsulfoxide.
  • the optical density (OD) of the plates is read, after homogenization of the staining by stirring, using a spectrophotometer set at 570 nm, thus making it possible to know the relative quantity of living and metabolically active cells.
  • the cell viability of the epidermis was evaluated as follows.
  • the reconstituted epidermis was individually contacted with 150 ⁇ l of MTT and placed in the incubator for 1 hour. At the end of the incubation, the epidermis are recovered. The cells are then lysed and the crystals of Formazan blue dissolved, then 200 ⁇ l of dimethyl sulfoxide are added. After homogenization of the coloration by stirring, the plates are read by a spectrophotometer set at 570 nm.
  • the ability of the cells previously treated by the products under study to capture the radioactive precursors was evaluated by the method of withdrawal.
  • the radioactive precursors are added to the cultures after incubation with the combination of the invention.
  • the cells are then incubated for 20 minutes at 37 ° C. in the presence of [ 3 H] L-tyrosine (130 pmol., Specific activity 47 Ci / mmol).
  • the medium is removed by aspiration, then the cells are washed 3 times with serum-free medium to remove the radioactivity, then detached from the support and washed again with medium and finally centrifuged at 600 g for 5 minutes.
  • the cell pellet is taken up in 500 ⁇ of medium.
  • the cells are sonicated and then introduced into counting flasks. The radioactivity is measured in a scintillation counter with the presence of 5 ml of scintillation fluid (organic Ready, Beckman) containing 0.9% acetic acid.
  • the [ 14 C] L-tyrosine neosynthesis was evaluated by incorporation of [ 14 C] L-phenylalanine into human melanocytes in culture. Once captured, the phenylalanine is converted into a tyrosine effect, which results in the synthesis of melanin.
  • the culture medium is removed and the cells are then rinsed with PBS and placed in contact with Triton X-100 (Sima, France) at 1%, and then incubated for 10 minutes.
  • the enzymatic reaction is initiated by addition of L-dopamine (Sigma, France) to 10 mM in PBS devoid of Ca 2+ and Mg 2+ .
  • the tyrosinase activity is evaluated by measuring the absorption at 475 nm using a spectrophotometer.
  • the study shows that the extract of Tribulus terrestris, at concentrations of 0.05% and 0.1%, exhibits no cyto ⁇ toxicity.
  • the extract is cytotoxic from 0.2%.
  • Lot 1 negative control co-culture receiving no product.
  • Lot 2 positive control co-culture receiving koic acid (2%).
  • Lot 3 treated coculture Tribulus terrestris (0.05%).
  • Lot 4 co-cultivation treated Tribulus terrestris (0.1%). The effect on pigmentation was studied by evaluating the activity of tyrosinase and by evaluating the synthesis of melanin.
  • Tribulus terrestris extract leads to a significant decrease in tyrosinase activity comparable to that of kojic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a composition that can be used in dermatology and/or in cosmetics. The composition includes an effective amount of chaulmoogra oil and/or the components thereof as well as an extract of Tribulus terrestris, combined in a ratio of Tribulus terrestris to chaulmoogra oil of 1:1,000 to 1:5 by weight. The invention can be used in cosmetic and dermatological compositions for treating depigmented or non-pigmented areas of the skin.

Description

COMPOSITION A BASE D ' HUILE DE CHAULMOOGRA ET DE  COMPOSITION BASED ON CHAULMOOGRA OIL AND
TRIBULUS TERRESTRIS POUR LA PIGMENTATION DE LA PEAU .  TRIBULUS TERRESTRIS FOR THE PIGMENTATION OF THE SKIN.
La présente invention concerne une nouvelle composition à base d'huile de chaulmoogra et de Tribulus terrestris utilisable en cosmétique, plus particulièrement pour la pigmentation de la peau. The present invention relates to a new composition based on chaulmoogra oil and Tribulus terrestris used in cosmetics, more particularly for the pigmentation of the skin.
La peau comprend des couches superficielles, à savoir l'épiderme, et des couches plus profondes, le derme et l'hypoderme, et chacune possède des propriétés spécifiques permettant à l'ensemble de réagir et s'adapter aux conditions de son environnement. L'épiderme, qui est composé de trois types de cellules, à savoir des kératinocytes (90% des cellules épidermiques ) , des mélanocytes (2 à 3% des cellules épidermiques ) et des cellules de Langerhans, constitue la couche externe et joue un rôle fondamental pour assurer la protection et le maintien d'une bonne trophicité. Le derme sert de support à l'épiderme et est principalement constitué de fibroblastes et d'une matrice extracellulaire essentiel¬ lement à base de collagène et d'élastine. Les fibres de collagène contribuent à la texture et la tonicité de la peau et l'élastine est responsable de son élasticité. D'autres cellules, comme les macrophages et les leucocytes, sont également présentes dans la couche du derme. L'hypoderme, qui est la couche la plus profonde de la peau, contient les adipocytes qui produisent des lipides pour que le tissu sous- cutané fabrique une couche grasse protégeant les muscles, les os et les organes internes contre les chocs. The skin consists of superficial layers, namely the epidermis, and deeper layers, the dermis and hypodermis, and each has specific properties allowing the whole to react and adapt to the conditions of its environment. The epidermis, which is composed of three types of cells, namely keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, constitutes the outer layer and plays a role. fundamental to ensure the protection and maintenance of good trophicity. The dermis serves as a support for the epidermis and is mainly composed of fibroblasts and an essential extracellular matrix ¬ lement based on collagen and elastin. Collagen fibers contribute to the texture and tone of the skin and elastin is responsible for its elasticity. Other cells, such as macrophages and leucocytes, are also present in the dermis layer. The hypodermis, which is the deepest layer of the skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects the muscles, bones, and internal organs from shock.
La pigmentation de la peau résulte de la présence de mélanine dans l'épiderme et le derme. La mélanine est un pigment produit par les mélanocytes situés principalement dans la couche basale, en présence de la tyrosinase (ou monophénol mono-oxygénase ) , une enzyme cupro-protéique qui catalyse la transformation de la L-tyrosine en L-dihydroxyphénylalanine (L-dopa) qui est ensuite oxydée en dopaquinone, puis en  The pigmentation of the skin results from the presence of melanin in the epidermis and the dermis. Melanin is a pigment produced by melanocytes located mainly in the basal layer, in the presence of tyrosinase (or monophenol monooxygenase), a cuproprotein enzyme that catalyzes the transformation of L-tyrosine into L-dihydroxyphenylalanine (L- dopa) which is then oxidized to dopaquinone, then
B10059wo dopachrome, pour aboutir à la mélanine suivant un mécanisme complexe. Cette biosynthèse, ou mélanogenèse, est un processus complexe, aujourd'hui relativement bien connu, où la tyrosi- nase joue un rôle essentiel. B10059wo dopachrome, to achieve melanin following a complex mechanism. This biosynthesis, or melanogenesis, is a complex process, nowadays relatively well known, in which tyrosinase plays an essential role.
Dans des conditions normales, la pigmentation de la peau est uniforme. Toutefois, on observe fréquemment l'apparition d'une hyperpigmentation, c'est-à-dire une pigmentation excessive localement, qui peut se manifester par des taches de rousseur, des taches de vieillissement, une pigmentation due à une exposition excessive au soleil, une hyperpigmentation post-inflammatoire due à l'abrasion, etc. A l'inverse, il est parfois souhaitable de favoriser la pigmentation de la peau pour des raisons esthétiques ou pour lutter contre les effets de certaines affections, comme par exemple le vitiligo, le lentigo dépigmenté, certaines mycoses, les traces de vergetures, des brûlures, etc, qui se traduisent par un défaut localisé de pigmentation.  Under normal conditions, the pigmentation of the skin is uniform. However, the appearance of hyperpigmentation, that is to say excessive pigmentation locally, which can be manifested by freckles, age spots, pigmentation due to excessive exposure to the sun, is frequently observed. post-inflammatory hyperpigmentation due to abrasion, etc. Conversely, it is sometimes desirable to promote the pigmentation of the skin for aesthetic reasons or to fight against the effects of certain diseases, such as for example vitiligo, depigmented lentigo, certain mycoses, traces of stretch marks, burns , etc., which result in a localized defect of pigmentation.
De nombreuses substances sont connues pour favoriser la mélanogénèse et la pigmentation de la peau, et par exemple des caroténoïdes et certaines vitamines telles que la vitamine E et la vitamine C. On connaît aussi, comme composés favorisant la synthèse de la mélanine, des alpha-hydroxy acides comme dans la demande de brevet WO 99.51198, des extraits de plantes, notamment Sanguisorba officinalis comme dans le brevet EP 993.826, ou encore des composés activant l'expression de la tyrosinase comme des psoralènes. La demande de brevet WO 03082227 décrit une composition destinée à réguler la mélanogénèse, qui comprend à la fois des promoteurs et des inhibiteurs de la synthèse de la mélanine.  Many substances are known to promote melanogenesis and pigmentation of the skin, and for example carotenoids and certain vitamins such as vitamin E and vitamin C. Melanin synthesis compounds are also known hydroxy acids as in the patent application WO 99.51198, plant extracts, in particular Sanguisorba officinalis as in patent EP 993,826, or compounds promoting the expression of tyrosinase as psoralens. The patent application WO 03082227 describes a composition for regulating melanogenesis, which comprises both promoters and inhibitors of melanin synthesis.
Certains polyphénols ont aussi été proposés pour renforcer la pigmentation de la peau. Ainsi, la demande de brevet FR 2.851.916 décrit l'utilisation de polyphénols catéchiques afin de favoriser la pigmentation naturelle de la peau, et par exemple des extraits de cacao utilisables dans des compositions pour administration par voie orale. Des extraits de xanthines peuvent être utilisés dans des composi¬ tions cosmétiques et dermatologiques pour favoriser la pigmentation de la peau, comme ceux obtenus à partir de graines de cacaoyer décrits dans le brevet FR 2.654.935. Some polyphenols have also been proposed to enhance the pigmentation of the skin. Thus, patent application FR 2 851 916 describes the use of catechol polyphenols in order to promote the natural pigmentation of the skin, and for example cocoa extracts that can be used in compositions for oral administration. of the xanthine extracts can be used in cosmetic and dermatological composi ¬ tions to promote pigmentation of the skin, such as those obtained from cocoa beans described in FR 2654935.
L'huile de chaulmoogra a longtemps été utilisée en médecine traditionnelle en Asie, notamment en Inde et en Chine, pour le traitement de la lèpre, avant l'apparition de médicaments à base de sulfones, notamment la diaminodiphényl- sulfone, et des antibiotiques antituberculeux tels que la rifampicine et la rifamycine. Il a été démontré que l'acide hydnocarpique, l'un des principaux constituants de l'huile de chaulmoogra, présente une activité antimycobactérienne en inhibant la multiplication de certaines mycobactéries telles que Mycobacterium leprae, comme indiqué par P.L. Jacobsen et L. Levy, Antimycobacterial Agents and Chemotherapy (1973) pp. 373-379.  Chaulmoogra oil has long been used in traditional medicine in Asia, particularly in India and China, for the treatment of leprosy, before the emergence of sulfonated drugs, including diaminodiphenylsulfone, and anti-tuberculosis antibiotics. such as rifampicin and rifamycin. Hydnocarpic acid, one of the main constituents of chaulmoogra oil, has been shown to exhibit antimycobacterial activity by inhibiting the growth of certain mycobacteria, such as Mycobacterium leprae, as indicated by PL Jacobsen and L. Levy, Antimycobacterial Agents and Chemotherapy (1973) pp. 373-379.
Le brevet FR 2.706.304 décrit l'utilisation d'huile de chaulmoogra comme composant de compositions cosmétiques destinées à harmoniser la pigmentation de la peau, grâce aux effets de pigmentation des zones cutanées achromiques, c'est- à-dire peu ou pas pigmentées, par migration de la pigmentation à partir de zones pigmentées. Le brevet FR 2.518.402 décrit une composition contenant de l'huile de chaulmoogra utilisable en cosmétique pour la normalisation des sécrétions sébacées et de la flore microbienne cutanée. Le brevet FR 2.876.908 montre que les huiles de chaulmoogra ont aussi des effets lipo- lytiques utiles dans des compositions destinées au traitement des surcharges adipeuses.  Patent FR 2,706,304 describes the use of chaulmoogra oil as a component of cosmetic compositions intended to harmonize the pigmentation of the skin, thanks to the pigmentation effects of the achromic cutaneous zones, that is to say little or no pigmented areas. , by migration of pigmentation from pigmented areas. Patent FR 2,518,402 describes a composition containing chaulmoogra oil that can be used in cosmetics for the normalization of sebaceous secretions and cutaneous microbial flora. FR 2,876,908 shows that chaulmoogra oils also have lipolytic effects useful in compositions intended for the treatment of fat overloads.
Les huiles de chaulmoogra sont essentiellement obtenues par extraction des graines de plantes ligneuses de la famille des Flacourtiacées , poussant dans des régions tropicales, notamment d'un arbre des espèces Hydnocarpus wightiana et Taraktogenos kurzii. Ces plantes sont essentiellement d'ori¬ gine asiatique, notamment d'Inde, du Viêt-nam et des Philippines, ainsi que d'Afrique centrale et d'Amérique du sud, notamment du Brésil. Chaulmoogra oils are mainly obtained by extracting the seeds of woody plants of the family Flacourtiaceae, growing in tropical regions, including a tree species Hydnocarpus wightiana and Taraktogenos kurzii. These plants are mainly Asian ori ¬ gine, including India, Vietnam and Philippines, as well as Central and South America, including Brazil.
Les graines d'où sont extraites les huiles de chaulmoogra contiennent une forte proportion de lipides, comprise entre 30 et 50% selon les espèces, 15 à 20% de protides et 4 à 6% de matières minérales, ainsi que 1 à 3% d ' insaponifiables, des glycérides d'acides gras insaturés à cycle penténique, consti¬ tués essentiellement par l'acide chaulmoogrique, l'acide hydnocarpique et l'acide gorlique. Il semble que ces acides soient responsables de l'action antimycobactérienne utile en thérapeutique dans le traitement traditionnel de la lèpre. On a observé que la structure spatiale de ces acides se rapproche du noyau cyclopentanoperhydroxyphénantrène caractéristique des stérols . The seeds from which the chaulmoogra oils are extracted contain a high proportion of lipids, between 30 and 50% depending on the species, 15 to 20% of proteins and 4 to 6% of mineral matter, as well as 1 to 3% of 'unsaponifiables, glycerides of unsaturated fatty acids to pentenoic cycle, consti ¬ essentially killed by chaulmoogric acid, hydnocarpic acid and gorlique acid. It seems that these acids are responsible for the therapeutic antimycobacterial action in the traditional treatment of leprosy. It has been observed that the spatial structure of these acids is similar to the cyclopentanoperhydroxyphenantrene ring characteristic of sterols.
Les acides chaulmoogrique, hydnocarpique et gorlique peuvent être représentés par les formules générales suivantes, respectivement :  The acids chaulmoogric, hydnocarpic and gorlic can be represented by the following general formulas, respectively:
Figure imgf000005_0001
CH-<C¾4 - OOOH
Figure imgf000005_0002
Figure imgf000005_0001
CH- <C¾4 - OOOH
Figure imgf000005_0002
Ces trois acides comprennent le même cycle cyclo- penténique portant un groupe acide à l'extrémité d'une chaîne carbonée -(CH2)n _ où n est 10 dans le cas de l'acide hydno¬ carpique et 12 dans le cas de l'acide chaulmoogrique, cette même chaîne comportant une double liaison dans le cas de l'acide gorlique. Les teneurs en chacun de ces trois acides dans les huiles de chaulmoogra varient selon l'origine des espèces . On trouve également dans les huiles de chaulmoogra des acides gras du type palmitique, oléique, palmitoléique, stéarique, myristique, et des traces d'acide aleprique et aleprilique . These three acids include the same pentenoic cycloaliphatic ring having an acid group at the end of a carbon chain - (CH2) n _ wherein n is 10 in the case of acid hydno ¬ carpique and 12 in the case of chaulmoogric acid, this same chain having a double bond in the case of gorlic acid. The contents of each of these three acids in chaulmoogra oils vary according to the origin of the species. Chaulmoogra oils also contain fatty acids such as palmitic, oleic, palmitoleic, stearic, myristic, and traces of alepric and aleprylic acid.
Le Tribulus terrestris (tribule terrestre) est une plante de la famille des zygophyllacées . C'est une herbe rampante peu ramifiée, à petite fleur jaune et à fruits très épineux, espèce indigène dans le Sud de la France qui est répandue dans les régions arides et incultes d'Afrique et d'Asie. Elle contient une essence, des saponosides stéroïdiques dont la génine peut être la diosgénine et la trigogénine. Consommée en l'état, elle provoque des intoxications chez le mouton par obturation des canaux hépatiques comme l'indiquent M.R. Aslani et al., Vet . Res. Commun. 27, 53-62 (2003) . Elle est parfois utilisée comme stimulant sexuel, et des tests sur la souris, en administration orale, ont fait apparaître une augmentation du taux de testostérone et du volume spermatique, comme indiqué par exemple par K. Gauthaman, Phytomedicine, 15, 44-54 (2008) .  Tribulus terrestris (terrestrial tribulus) is a plant of the zygophyllaceae family. It is a creeping little branched herb with a small yellow flower and very spiny fruit, a native species in southern France that is widespread in the arid and uncultivated regions of Africa and Asia. It contains one essence, steroidal saponosides whose genin may be diosgenin and trigogenin. Consumed as it is, it causes intoxication in sheep by clogging of the hepatic ducts as reported by R. R. Aslani et al., Vet. Res. Common. 27, 53-62 (2003). It is sometimes used as a sexual stimulant, and tests on the mouse, in oral administration, have shown an increase in testosterone and sperm volume, as indicated for example by K. Gauthaman, Phytomedicine, 15, 44-54 ( 2008).
Le brevet CN 101406511 décrit une composition topique associant plusieurs substances d'origine végétale et notamment des extraits de fruit de Malaytea scurfpea, de fruit de Cnidium, de Chaulmoogra et de Tribulus terrestris ou de Astragalus complanatus, ainsi que des dérivés métalliques (litharge et chlorure mercureux) , en quantités sensiblement équivalentes, et cette composition pourrait être utile pour le traitement du vitiligo.  The patent CN 101406511 describes a topical composition combining several substances of vegetable origin and in particular extracts of fruit of Malaytea scurfpea, fruit of Cnidium, Chaulmoogra and Tribulus terrestris or Astragalus complanatus, as well as metal derivatives (litharge and chloride mercureux), in substantially equivalent amounts, and this composition could be useful for the treatment of vitiligo.
Le brevet KR 20090056778 décrit des compositions asso¬ ciant des herbes médicinales, en particulier Hydnocarpi semen, Sesamum indicum, Dictamni radicis cortex, Mormodicae semen et Tribulus terrestris en proportions sensiblement équivalentes, pour le traitement d'allergies cutanées, notamment la dermite atopique et des allergies à des piqûres d'insectes et à des médicaments . Les études réalisées par la demanderesse sur des mélano- cytes humains et des épidermes reconstitués ont montré que le Tribulus terrestris, utilisé isolément par voie topique sous forme d'extraits hydroglycoliques , a des effets dépigmentants significatifs bien que faibles. KR 20090056778 discloses compositions of asso ¬ ting medicinal herbs, in particular Hydnocarpi semen, Sesamum indicum, Dictamni radicis cortex, Mormodicae semen and Tribulus terrestris in substantially equal proportions, for the treatment of skin allergies, in particular atopic dermatitis and allergies to insect bites and drugs. The studies carried out by the applicant on human melanocytes and reconstituted epidermis have shown that tribulus terrestris, used topically in the form of hydroglycolic extracts, has significant but weak depigmenting effects.
Par contre, les études réalisées par la demanderesse ont montré de manière inattendue que l'association d'huile de chaulmoogra et de Tribulus terrestris dans un rapport en poids Tribulus terrestris / huile de chaulmoogra compris entre 1:1.000 et 1:5, présente un effet pigmentant significatif susceptible d'agir dans toutes les étapes de la pigmentation, et supérieur à celui du chaulmoogra utilisé isolément.  On the other hand, the studies carried out by the Applicant have unexpectedly shown that the combination of Chaulmoogra oil and Tribulus terrestris in a weight ratio Tribulus terrestris / Chaulmoogra oil of between 1: 1,000 and 1: 5, presents a significant pigmenting effect capable of acting in all stages of pigmentation, and greater than that of chaulmoogra used alone.
La présente invention a donc pour objet une nouvelle composition cosmétique associant de l'huile de chaulmoogra et/ou ses composants et un extrait de Tribulus terrestris, en concentrations appropriées, et plus particulièrement dans un rapport en poids extrait de Tribulus terrestris / huile de chaulmoogra compris entre 1:1.000 et 1:5, pour le traitement des zones dépigmentées ou non pigmentées de la peau.  The subject of the present invention is therefore a new cosmetic composition combining chaulmoogra oil and / or its components and an extract of Tribulus terrestris, in appropriate concentrations, and more particularly in a weight ratio extracted from Tribulus terrestris / chaulmoogra oil. from 1: 1,000 to 1: 5, for the treatment of depigmented or unpigmented areas of the skin.
L'invention a également pour objet l'utilisation de l'huile de chaulmoogra, ou de ses composants essentiels tels que les acides chaulmoogrique, hydnocarpique et gorlique, ainsi que leurs sels et esters, et d'extraits de Tribulus terrestris pour la préparation d'une composition cosmétique pour le traitement des zones dépigmentées ou non pigmentées de la peau.  The invention also relates to the use of chaulmoogra oil, or its essential components such as chaulmoogric, hydnocarpic and gorlic acids, as well as their salts and esters, and extracts of Tribulus terrestris for the preparation of a cosmetic composition for the treatment of depigmented or non-pigmented areas of the skin.
L'invention a aussi pour objet l'utilisation en cosmétique de l'association d'un extrait de Tribulus terrestris et d'huile de chaulmoogra dans un rapport en poids Tribulus terrestris / huile de chaulmoogra compris entre 1:1.000 et 1:5, pour la pigmentation de la peau.  The subject of the invention is also the use in cosmetics of the combination of an extract of Tribulus terrestris and of chaulmoogra oil in a weight ratio Tribulus terrestris / chaulmoogra oil of between 1: 1,000 and 1: 5, for the pigmentation of the skin.
L'invention a encore pour objet un procédé de traitement cosmétique non thérapeutique de la peau, et plus particuliè¬ rement pour repigmenter les zones non pigmentées ou dépigmen- tées de la peau, par application d'une composition à base d'huile de chaulmoogra et d'extrait de Tribulus terrestris en concentrâtiosn appropriées sur la zone de la peau nécessitant un tel traitement. The invention further relates to a non-therapeutic cosmetic treatment process for the skin, more particuliè ¬ surely repigment for non-pigmented areas or dépigmen- Tees skin by applying a composition based on of Chaulmoogra oil and Tribulus terrestris extract in appropriate concentration on the area of the skin requiring such treatment.
Les composants de l'huile de chaulmoogra sont de préférence les acides chaulmoogrique, hydnocarpique et gorlique ainsi que leurs sels et esters, qui peuvent être choisis parmi les esters de méthyle, d'éthyle ou de benzyle, ainsi que les sels de sodium ou de potassium.  The components of the chaulmoogra oil are preferably the chaulmoogric, hydnocarpic and gorlic acids and their salts and esters, which may be chosen from methyl, ethyl or benzyl esters, as well as sodium or potassium.
Les sels ou esters des acides chaulmoogrique, hydno- carpique et gorlique peuvent être choisis parmi les esters de méthyle, d'éthyle ou de benzyle, ainsi que les sels de sodium ou de potassium, et par exemple le chaulmoograte de sodium ou de potassium et 1 'hydnocarpate de sodium.  The salts or esters of chaulmoogric, hydropyric and gorlic acids may be chosen from methyl, ethyl or benzyl esters, as well as sodium or potassium salts, and for example sodium or potassium chaulmoograte and Sodium hydnocarpate.
L'activité pigmentante de l'huile de chaulmoogra serait essentiellement due aux acides chaulmoogrique, hydnocarpique et gorlique qu'elle contient, et les expérimentations effectuées ont montré que l'association avec un extrait de Tribulus terrestris procure de manière inattendue une amélioration de cette activité connue du Chaulmoogra alors que le Tribulus, utilisé isolément, a une action dépigmentante.  The pigmenting activity of chaulmoogra oil is mainly due to the chaulmoogric, hydnocarpic and gorlic acids it contains, and the experiments carried out have shown that the association with an extract of Tribulus terrestris unexpectedly provides an improvement in this activity. known from Chaulmoogra whereas Tribulus, used alone, has a depigmenting action.
Plus particulièrement, il a été démontré que l'asso¬ ciation d'huile de chaulmoogra et d'extrait de Tribulus terrestris Specifically, it was shown that the asso ¬ ciation of Chaulmoogra oil and extract of Tribulus terrestris
• présente une parfaite innocuité vis-à-vis des cellules endothéliales de l'épiderme et des mélanocytes humains en culture ;  • presents a perfect safety vis-à-vis the endothelial cells of the epidermis and human melanocytes in culture;
• induit un effet significatif sur l'activité de la tyrosi- nase même en l'absence d'irradiation UV ;  • induces a significant effect on the activity of tyrosinase even in the absence of UV irradiation;
• induit un effet significatif sur la capture de L-tyrosine et de L-phénylalanine ainsi que sur la synthèse de L- tyrosine en l'absence d'irradiation UV tandis que l'effet n'est pas significatif en présence d'irradiation UV ;  • induces a significant effect on the uptake of L-tyrosine and L-phenylalanine as well as on the synthesis of L-tyrosine in the absence of UV irradiation while the effect is not significant in the presence of UV irradiation ;
• présente de tels effets dans toutes les étapes du processus de pigmentation, procurant une amélioration par rapport à l'utilisation du Chaulmoogra isolément. Les études ont montré que cet effet est remarquable avec une faible proportion de Tribulus terrestris par rapport au Chaulmoogra (rapport en poids entre 1:200 et 1:20) alors que les essais montrent que le Triibulus terrestris, en concen- tration équivalente, mais utilisé isolément, a un effet dépig¬ mentant . • exhibits such effects in all stages of the pigmentation process, providing an improvement over the use of Chaulmoogra alone. Studies have shown that this effect is remarkable with a small proportion of Tribulus terrestris compared to Chaulmoogra (weight ratio between 1: 200 and 1:20), whereas trials show that Triibulus terrestris, in equivalent concentration, used alone, has a dépig ¬ menting effect.
Les huiles de chaulmoogra utilisées dans la présente invention peuvent être extraites des graines de plantes de variétés telles que Hydnocarpus wightiana, Taraktogenos kurzii, Hydnocarpus alpina, Hydnocarpus anthelmintica, Hydnocarpus cauliflora, Hydnocarpus dawnensis, Hydnocarpus heterophylla, Hydnocarpus hutchinsonii , Hydnocarpus ovoïdea, Hydnocarpus subfalcata, Hydnocarpus venenata, Hydnocarpus verrucosa, Hydnocarpus woodii, Hydnocarpus calvipetala, Hydno- carpus ilicifolia, Hydnocarpus octandra, Gynocardia odorata, Oncoba echinata, Caloncoba glauca, Caloncoba welwitschii, Carpotroche brasiliensis , Carpotroche amazonica, Asteriastigma macrocarpa, Mayna odorata et Lindakeria dentata.  The chaulmoogra oils used in the present invention can be extracted from the seeds of plants of varieties such as Hydnocarpus wightiana, Taraktogenos kurzii, Hydnocarpus alpina, Hydnocarpus anthelmintica, Hydnocarpus cauliflora, Hydnocarpus dawnensis, Hydnocarpus heterophylla, Hydnocarpus hutchinsonii, Hydnocarpus ovoidea, Hydnocarpus subfalcata, Hydnocarpus venenata, Hydnocarpus verrucosa, Hydnocarpus woodii, Hydnocarpus calvipetala, Hydnocarpus ilicifolia, Hydnocarpus octandra, Gynocardia odorata, Oncoba echinata, Caloncoba glauca, Caloncoba welwitschii, Carpotroche brasiliensis, Carpotroche amazonica, Asteriastigma macrocarpa, Mayna odorata and Lindakeria dentata.
Les extraits de Tribulus terrestris sont préparés à partir de plantes séchées, l'extrait pouvant représenter de 1 à 20% environ du poids total de la plante.  Extracts of Tribulus terrestris are prepared from dried plants, the extract may represent from 1 to 20% of the total weight of the plant.
On peut par exemple préparer suivant les techniques usuelles des extraits hydro-alcooliques, plus particulièrement des extraits hydroglycoliques ou hydroéthanoliques , ou encore des extraits hydroglycérinés . Après séchage et pulvérisation des plantes, l'extraction peut se faire par exemple par perco- lation ou macération à raison de 100 g de plante pour 500 g d'eau. Le gâteau est exprimé et les liqueurs réunies et complétées à 500 g par addition de glycol tel que le butylène glycol et le propylène glycol.  For example, hydroalcoholic extracts may be prepared, for example, by way of the usual techniques, more particularly hydroglycolic or hydroethanolic extracts, or even hydroglycerinated extracts. After drying and spraying the plants, the extraction can be done for example by percolation or maceration at 100 g of plant per 500 g of water. The cake is expressed and the liquors combined and supplemented to 500 g by addition of glycol such as butylene glycol and propylene glycol.
Les extraits de Tribulus terrestris utilisés dans les compositions suivant la présente invention sont de préférence sous forme d'extraits hydroglycoliques, par exemple dans le butylène glycol, de la plante entière séchée et réduite en poudre ou, de préférence, des graines ou des fruits séchés et réduits en poudre. The extracts of Tribulus terrestris used in the compositions according to the present invention are preferably in the form of hydroglycolic extracts, for example in butylene glycol, of the whole plant dried and reduced to powder or, preferably, seeds or fruits dried and reduced to powder.
Suivant une forme avantageuse de réalisation, l'extrait utilisable dans la composition de l'invention est obtenu à partir des fruits séchés et réduits en poudre, que l'on fait macérer dans un mélange de glycol et d'eau, par exemple un mélange 50/50 de glycol et d'eau, puis on procède à une décantation, une clarification, si nécessaire, et une filtra- tion. La clarification se fait généralement par centrifugation ou par addition d'une substance absorbant les microparticules, comme la cellulose, la polyvinyl pyrolidone ou des terres absorbantes. Le glycol peut être choisi parmi le butylène glycol-1,3, le butylène glycol-1,4, le dipropylène glycol, et on utilise de préférence le butylène glycol.  According to an advantageous embodiment, the extract that can be used in the composition of the invention is obtained from the dried and powdered fruits, which are macerated in a mixture of glycol and water, for example a mixture of 50/50 of glycol and water, followed by decantation, clarification, if necessary, and filtration. Clarification is usually by centrifugation or addition of a microparticle-absorbing substance, such as cellulose, polyvinyl pyrrolidone or absorbing soil. The glycol may be chosen from butylene glycol-1,3, butylene glycol-1,4, and dipropylene glycol, and butylene glycol is preferably used.
L'extrait hydroglycolique de Tribulus terrestris utilisé dans la présente invention se présente sous la forme d'un liquide de couleur jaune ambrée, d'odeur caractéristique, soluble dans l'eau et dans l'alcool, se caractérisant par :  The hydroglycolic extract of Tribulus terrestris used in the present invention is in the form of an amber-yellow liquid of characteristic odor, soluble in water and in alcohol, characterized by:
- matières sèches) 0,1-1,0 %  - dry matter) 0.1-1.0%
- pH 5,3-7,3  - pH 5.3-7.3
- indice de réfraction à 22°C 1,380-1,420 refractive index at 22 ° C 1,380-1,420
- densité à 22°C 1,000-1,050 Dans la composition selon l'invention, le rapport en poids de l'extrait de Tribulus terrestris à l'huile de chaul- moogra est compris entre 1:1.000 et 1:5 et de préférence entre 1:200 et 1:20. Density at 22 ° C. 1,000-1,050 In the composition according to the invention, the ratio by weight of the tribulus terrestris extract to the oil of chaulograogra is between 1: 1,000 and 1: 5 and preferably between 1: 200 and 1:20.
En particulier, la teneur en extrait de Tribulus terrestris peut être comprise entre 0,01 et 0,5%, et de préférence entre 0,05 et 0,2% en poids par rapport au poids total de la composition, tandis que la teneur en huile de chaulmoogra, ou en acides ou sels ou esters est généralement comprise entre 0,1 et 20%, et de préférence entre 2 et 10% par rapport au poids total de la composition, pour procurer les meilleurs effets pigmentants. L'huile de chaulmoogra, et ses acides ou esters, peuvent être utilisés avantageusement sous une forme encapsulée dans des liposomes. In particular, the extract content of Tribulus terrestris may be between 0.01 and 0.5%, and preferably between 0.05 and 0.2% by weight relative to the total weight of the composition, while the content in oil of chaulmoogra, or in acids or salts or esters is generally between 0.1 and 20%, and preferably between 2 and 10% relative to the total weight of the composition, to provide the best pigmenting effects. Chaulmoogra oil, and its acids or esters, can be used advantageously in a form encapsulated in liposomes.
Suivant une technique connue dans la fabrication des compositions cosmétiques, les liposomes sont constitués par des petites sphères creuses, de diamètre généralement inférieur à 500 nm, dont la paroi est formée d'une double couche de lipides tels que des glucolipides ou des phospho- lipides. Ils peuvent être obtenus par exemple par traitement aux ultrasons d'un mélange d'un soluté aqueux et de lipides. Les lipides (phospholipides ou glucolipides) se réorganisent dans une configuration où l'énergie de l'ensemble est minimale, donc thermodynamiquement la plus stable. Les liposomes sont utilisés dans l'industrie cosmétique pour délivrer des composés à l'intérieur des cellules lorsque le vésicule fusionne avec la membrane plasmique.  According to a known technique in the manufacture of cosmetic compositions, the liposomes are constituted by small hollow spheres, generally less than 500 nm in diameter, whose wall is formed of a double layer of lipids such as glucolipids or phospholipids . They can be obtained for example by ultrasonic treatment of a mixture of an aqueous solute and lipids. Lipids (phospholipids or glucolipids) are reorganized in a configuration where the energy of the whole is minimal, therefore thermodynamically the most stable. Liposomes are used in the cosmetics industry to deliver compounds into cells when the vesicle fuses with the plasma membrane.
Suivant une forme préférée de réalisation de l'invention, une partie au moins de l'huile de chaulmoogra est encapsulée dans des vésicules du type liposome.  According to a preferred embodiment of the invention, at least part of the chaulmoogra oil is encapsulated in liposome-type vesicles.
Les compositions conformes à la présente invention sont de préférence administrables par voie topique. Suivant la terminologie classique, l'administration par voie topique désigne toute méthode consistant à appliquer la substance ou la composition directement sur la peau, sur la zone nécessi- tant le traitement.  The compositions according to the present invention are preferably topically administrable. In conventional terminology, topical administration refers to any method of applying the substance or composition directly to the skin on the area requiring treatment.
Conformément à la présente invention, la composition administrable par voie topique peut avantageusement contenir, outre les composants de base décrits ci-dessus, une ou plusieurs autres substances connues pour exercer des effets complémentaires bénéfiques pour la peau, et plus particu¬ lièrement le tocophérol, la vitamine A (rétinol), l'acide rétinoïque, des agents bactéricides, de la théophylline, du monométhylsilanol , de la proline, ou encore du beurre de Karité, ainsi que des extraits végétaux tels que Camellia japonica. On peut aussi ajouter à la composition des extraits ou composés connus pour faciliter la pénétration des principes actifs de la composition à travers l'épiderme, par exemple 1 ' éthoxydiglycol et des saponosides du type hédéragénine . According to the present invention, the composition can be administered topically may advantageously contain, in addition to the basic components described above, one or more other substances known to exert beneficial complementary effects for the skin, and more particu ¬ larly tocopherol, vitamin A (retinol), retinoic acid, bactericidal agents, theophylline, monomethylsilanol, proline, or shea butter, as well as plant extracts such as Camellia japonica. It is also possible to add to the composition extracts or compounds known to facilitate the penetration of the active ingredients of the composition through the epidermis, for example ethoxydiglycol and saponosides of the hederagenin type.
Les compositions cosmétiques et pharmaceutiques conformes à la présente invention, sont destinées de préférence à une administration topique, et contiennent donc des supports et excipients couramment utilisés dans des compositions de ce type telles que des émulsions H/E ou E/H, des crèmes, des gels ou des lotions. Dans le cas des émulsions, la phase grasse peut représenter entre 10 et 60% environ du poids de la composition, la phase aqueuse entre 10 et 80% environ et l'agent émulsionnant entre 2 et 20%, le reste étant constitué par les composants de base indiqués ci-dessus et les autres composants mentionnés ci-après.  The cosmetic and pharmaceutical compositions in accordance with the present invention are preferably intended for topical administration, and therefore contain carriers and excipients commonly used in compositions of this type, such as O / W or W / O emulsions, creams, gels or lotions. In the case of emulsions, the fatty phase may represent between 10 and 60% of the weight of the composition, the aqueous phase between 10 and 80% and the emulsifier between 2 and 20%, the remainder being constituted by the components above and the other components listed below.
La composition peut encore contenir diverses substances et excipients choisis en fonction de leurs propriétés connues et de la forme galénique envisagée. Ainsi, on peut incorporer dans la composition des conservateurs, des agents émul- sionnants, des agents viscosants, des épaississants, des gélifiants, des antioxydants, des agents hydratants, des tensioactifs, des parfums, des huiles, des lipides, un solvant spécifique ainsi que de l'eau et divers additifs destinés à améliorer les propriétés physiques de la composition.  The composition may also contain various substances and excipients chosen according to their known properties and the intended dosage form. Thus, preservatives, emulsifiers, viscosifiers, thickeners, gelling agents, antioxidants, moisturizers, surfactants, perfumes, oils, lipids, a specific solvent and the like can be incorporated into the composition. only water and various additives to improve the physical properties of the composition.
On peut choisir l'agent émulsionnant parmi des polymères carboxyvinyliques à haut poids moléculaire (par exemple le  The emulsifier may be selected from high molecular weight carboxyvinyl polymers (e.g.
® ® ® ®
Carbopol ) , des polysorbates (par exemple le Tween 60 ou leCarbopol), polysorbates (eg Tween 60 or
Polysorbate 80 ®) , des esters de sorbitan et en particulier un monostéarate tel que le Span 60®, un tristéarate, un monopalmitate, et un laurate de sorbitan. On peut encore utiliser d'autres agents émulsionnants tels que divers dérivés d'acide stéarique ou palmitique, et par exemple le stéarate dePolysorbate 80®), sorbitan esters and in particular a monostearate such as Span 60® , a tristearate, a monopalmitate, and a sorbitan laurate. It is also possible to use other emulsifying agents such as various stearic or palmitic acid derivatives, and for example stearate of
PEG 100®, des mono- ou diglycérides d'acide stéarique ou palmitique, un stéarate de propylène glycol auto-émulsion- nable, ou encore le polyglycéryl-2-sesquioléate, 1 ' éther cétylique de polyoxyéthylène, un polyglucoside de siloxane, ou une silicone émulsionnable . On peut encore utiliser des mélanges émulsionnants non ioniques tels que le Protegin X . PEG 100®, mono- or diglycerides of stearic or palmitic acid, self-emulsifiable propylene glycol stearate, or polyglyceryl-2-sesquioleate, 1-ether polyoxyethylene cetyl, a siloxane polyglucoside, or an emulsifiable silicone. Nonionic emulsifying mixtures such as Protegin X may also be used.
Les agents viscosants utilisés dans les compositions de l'invention peuvent être choisis parmi divers polymères d'acide acrylique, un copolymère d'acrylate et de laurate d'acryloyle, une gomme cellulose, une silice, des polymères carboxyvinyliques , un silicate d'aluminium et de magnésium, et on peut utiliser par exemple la silice colloïdale vendue sous la marque Aerosil 200 ou un acide polyacrylique réticulé tel que le Carbopol 940 .  The viscosifying agents used in the compositions of the invention may be chosen from various polymers of acrylic acid, a copolymer of acrylate and acryloyl laurate, a cellulose gum, a silica, carboxyvinyl polymers, an aluminum silicate and magnesium, and it is possible to use, for example, the colloidal silica sold under the trademark Aerosil 200 or a crosslinked polyacrylic acid such as Carbopol 940.
Les gélifiants ou épaississants peuvent être choisis par exemple parmi les polyacrylamides , des acrylates comme le Pemulen®, les dérivés de cellulose comme 1 ' hydroxypropyl cellulose, ou les gommes naturelles.  The gelling agents or thickeners may be chosen for example from polyacrylamides, acrylates such as Pemulen®, cellulose derivatives such as hydroxypropyl cellulose, or natural gums.
Les agents hydratants utilisés peuvent être choisis par exemple parmi un polyol, le sorbitol, le maltitol, le penta- érythritol, les polyacrylates et polyméthacrylates de glycéryle, le glycérol ou des dérivés de glycérol. On peut aussi ajouter des émollients tels qu'un malate d'alkyle, 1 ' isohexadécane, des triglycérides d'acide caprique ou capry- lique, etc.  The moisturizing agents used may be chosen for example from a polyol, sorbitol, maltitol, pentaerythritol, glyceryl polyacrylates and polymethacrylates, glycerol or glycerol derivatives. It is also possible to add emollients such as alkyl malate, isohexadecane, capric or caprylic acid triglycerides and the like.
Les conservateurs usuels de la technique des compositions dermatologiques ou cosmétologiques peuvent être utilisés dans l'invention, et par exemple l'acide benzoïque et un p- hydroxybenzoate d'alkyle tel que le p-hydroxy-benzoate de méthyle (Méthylparaben) , un alcool tel que le phénoxy-éthanol ou encore la chlorphénésine ou 1 ' imidazolidinyl urée.  The usual preservatives of the technique of dermatological or cosmetological compositions can be used in the invention, and for example benzoic acid and an alkyl p-hydroxybenzoate such as methyl p-hydroxy-benzoate (Methylparaben), an alcohol such as phenoxyethanol or chlorphenesin or imidazolidinyl urea.
Les constituants de la phase grasse, c'est-à-dire les huiles et lipides, peuvent être choisis parmi l'huile de jojoba, l'huile de maïs, l'huile de vaseline, l'huile d'amandes douces, l'huile de coco hydrogénée, l'huile de carthame, des glycérides d'acides gras saturés, l'acide stéarique, l'acide palmitique, le stéarate d'octyle, le palmitate de glycéryle, le palmitate d'octyle, un triglycéride d'acides caprique et caprylique, le 2-octyl-dodécanol , le polyéthylène glycol, 1 ' adipate d'éthyl-2 hexyle, ou encore des huiles de silicones telles que le méthyl phényl polysiloxane, la diméthicone, la cyclométhicone et la phényl diméthicone. The constituents of the fatty phase, that is to say the oils and lipids, can be chosen from jojoba oil, corn oil, liquid petroleum jelly, sweet almond oil, hydrogenated coconut oil, safflower oil, saturated fatty acid glycerides, stearic acid, palmitic acid, octyl stearate, glyceryl palmitate, octyl palmitate, triglyceride caprylic and caprylic acids, 2-octyl-dodecanol, polyethylene glycol, 2-ethyl hexyl adipate, or silicone oils such as methyl phenyl polysiloxane, dimethicone, cyclomethicone and phenyl dimethicone .
La composition peut aussi contenir un solvant choisi en fonction des composants utilisés et de la forme d'adminis¬ tration envisagée. Le solvant peut être par exemple de l'eau, et de préférence de l'eau déminéralisée, ou un solvant spécifique tel que le propylène glycol, un éther de diéthylène glycol, ou un alcool tel que l'éthanol. The composition may also contain a solvent selected depending on the components used and the adminis tration form ¬ envisaged. The solvent may be, for example, water, and preferably demineralized water, or a specific solvent such as propylene glycol, a diethylene glycol ether, or an alcohol such as ethanol.
Des agents de protection contre les rayons ultraviolets peuvent aussi être avantageusement incorporés dans les compositions, et par exemple des filtres solaires UV-A et UV-B hydrophiles ou lipophiles, choisis parmi la benzophénone ou un dérivé de benzophénone tel que la 2-hydroxy-4-méthoxy- benzophénone (Eusolex® 4360), ou un ester d'acide cinnamique et plus particulièrement le méthoxycinnamate d'octyle (Eusolex® 2292), le méthoxycinnamate d ' éthyl-2-hexyle (Parsol MCX®) , ou encore un cyano-β, β-diphénylacrylate tel que l'octo- crylène (Eusolex® OCR) , le 4-méthylbenzylidène camphre (Eusolex 6300®) , et des dérivés du dibenzoylméthane tels que le 4-isopropyl dibenzoylméthane (Eusolex 8020), le t-butyl- méthoxy dibenzoylméthane (Parsol 1789®), et le 4-méthoxy- dibenzoylméthane . On peut aussi utiliser des pigments formant écran anti-ultraviolet, comme par exemple le dioxyde de titane, l'oxyde de zinc, l'oxyde de zirconium ou encore l'oxyde d'aluminium.  Ultraviolet protection agents may also advantageously be incorporated in the compositions, and for example hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from benzophenone or a benzophenone derivative such as 2-hydroxybenzophenone. 4-methoxybenzophenone (Eusolex® 4360), or a cinnamic acid ester and more particularly octyl methoxycinnamate (Eusolex® 2292), ethyl-2-hexyl methoxycinnamate (Parsol MCX®), or a cyano-β, β-diphenylacrylate such as octo-crylene (Eusolex® OCR), 4-methylbenzylidene camphor (Eusolex 6300®), and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane (Eusolex 8020), t -butyl-methoxy dibenzoylmethane (Parsol 1789®), and 4-methoxydibenzoylmethane. It is also possible to use anti-ultraviolet screen pigments, such as, for example, titanium dioxide, zinc oxide, zirconium oxide or aluminum oxide.
Le pH de la composition est de préférence compris entre 5,3 et 7,5, et peut être ajusté, selon les compositions, par addition d'un acide tel que l'acide citrique ou d'une base telle que l'hydroxyde de sodium ou de potassium.  The pH of the composition is preferably between 5.3 and 7.5, and may be adjusted, depending on the compositions, by the addition of an acid such as citric acid or a base such as sodium or potassium.
La composition conforme à la présente invention peut être présentée sous les formes classiquement utilisées pour une application topique, c'est-à-dire sous forme de gel, lotion, émulsion (en particulier crème ou lait), patchs transdermi- ques, masque ou pommade, contenant des excipients et supports usuels compatibles et pharmaceutiquement acceptables. Ces formes d'administration par voie topique sont préparées par les techniques connues, et par exemple, dans le cas d'une crème, par dispersion d'une phase grasse dans une phase aqueuse pour obtenir une émulsion huile dans eau, ou inversement pour préparer une émulsion eau dans huile. Dans le cas de crèmes, on préfère utiliser des émulsions à structure lamellaire contenant peu de produits éthoxylés ou n'en contenant pas du tout. L'huile de chaulmoogra est de préférence préalablement chauffée avant d'être incorporée à la phase grasse, tandis que l'extrait de Tribulus terrestris utilisé en association est introduit dans la phase aqueuse ou alcoolique . The composition according to the present invention may be presented in the forms conventionally used for topical application, that is to say in the form of gel, lotion, emulsion (in particular cream or milk), transdermal patches. mask or ointment containing compatible and pharmaceutically acceptable excipients and carriers. These forms of topical administration are prepared by the known techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion. In the case of creams, it is preferred to use lamellar structure emulsions containing little or no ethoxylated products. The chaulmoogra oil is preferably preheated before being incorporated into the fatty phase, while the Tribulus terrestris extract used in combination is introduced into the aqueous or alcoholic phase.
A titre d'exemple, on peut préparer des compositions topiques conformes à l'invention sous forme de crèmes, de laits ou de gels, utilisables en une ou plusieurs applications quotidiennes, la durée du traitement pouvant être généralement de l'ordre de un à trois mois.  By way of example, it is possible to prepare topical compositions in accordance with the invention in the form of creams, milks or gels, which can be used in one or more daily applications, the duration of the treatment being generally of the order of one to four. three months.
Les exemples de compositions donnés ci-après illustrent l'invention sans en limiter la portée. Sauf indication contraire, les parties et pourcentages sont indiqués en poids.  The examples of compositions given below illustrate the invention without limiting its scope. Unless otherwise indicated, parts and percentages are by weight.
Exemple 1 Example 1
Une crème antivergeture à base d'huile de chaulmoogra et d'extrait de Tribulus terrestris ayant la composition indiquée ci-après est préparée suivant les techniques usuelles :  An anti stretch mark cream based on chaulmoogra oil and Tribulus terrestris extract having the composition indicated below is prepared according to the usual techniques:
Phase A  Phase A
Eau déminéralisée q . s . p . 100,00 Demineralized water q. s. p. 100.00
Glycérine 2,00 Pentylène glycol 5, 00Glycerin 2.00 Pentylene Glycol 5.00
Bentonite 1,00Bentonite 1.00
Ethyl hexyl glycérine 0,20 Dehydroacétate de sodium 0,10 Phase B Ethyl Hexyl Glycerine 0.20 Sodium Dehydroacetate 0.10 Phase B
Alcools C12-C16 et acide palmitique  C12-C16 alcohols and palmitic acid
et lécithine hydrogénée 5,00 and hydrogenated lecithin 5.00
Triglycérides caprique / caprylique 5,00 Squalane 3,00Capric / caprylic triglycerides 5.00 Squalane 3.00
Beurre de Karité 3,00Shea Butter 3.00
Ester glycérique de vitamine F 1,00Glycerol ester of vitamin F 1.00
Alcool béhénylique 2,50Behenyl alcohol 2.50
Cire d' abeille 2, 00 Huile de tournesol 5,00Beeswax 2, 00 Sunflower oil 5,00
Undécylénate de glycéryle 0,10Glyceryl undecylenate 0.10
Tocophérol 0,70Tocopherol 0.70
Huile de chaulmoogra 10,00 Phase C Chaulmoogra Oil 10.00 Phase C
Eau déminéralisée 10,00 Xylityl glucoside et anhydro-xylitol  Demineralized water 10.00 Xylityl glucoside and anhydro-xylitol
et xylitol 1,00 and xylitol 1.00
Monométhyl silanol 1,00Monomethyl silanol 1.00
Proline 1,00 Extrait de Camellia japonica 5,00Proline 1.00 Extract of Camellia japonica 5.00
Extrait de Tribulus terrestris 0,10 Phase D Tribulus terrestris extract 0.10 Phase D
Parfum 0,50 Perfume 0,50
La phase aqueuse A est chauffée à 70-75°C tandis que la phase grasse B est chauffée à environ 75°C, puis les deux phases sont mélangées soigneusement sous agitation. La phase C, après homogénéisation, est ajoutée au mélange à la température d'environ 35°C. L'ensemble est mélangé et refroidi progressivement . The aqueous phase A is heated to 70-75 ° C while the fat phase B is heated to about 75 ° C, and then the two phases are thoroughly mixed with stirring. Phase C, after homogenization, is added to the mixture at a temperature of about 35 ° C. The whole is mixed and gradually cooled.
Cette crème antivergeture est utilisée en application topique, une fois à deux fois par jour sur les zones de la peau à traiter, pendant une période de 1 à 3 mois selon l'importance de la dépigmentation à traiter. Les premiers effets significatifs peuvent être observés dès la fin de la 4ème semaine, sous forme d'une atténuation du contraste entre zone dépigmentée et zone normalement pigmentée et ces effets repigmentants vont en s 'amplifiant dans la suite du traitement . This anti stretch mark cream is used topically, once to twice a day on the areas of the skin to be treated, for a period of 1 to 3 months depending on the importance of the depigmentation to be treated. The first significant effects can be observed as of the end of the 4th week, in the form of an attenuation of the contrast between depigmented zone and normally pigmented zone and these repigmenting effects are amplified in the continuation of the treatment.
Exemple 2 Example 2
Une crème solaire à base d'huile de chaulmoogra et d'extrait de Tribulus terrestris ayant la composition indiquée ci-après est préparée suivant les techniques usuelles :  A sunscreen based on chaulmoogra oil and Tribulus terrestris extract having the composition indicated below is prepared according to the usual techniques:
Phase A  Phase A
Tween 60 3,50 Span 60 2,50 Tween 60 3.50 Span 60 2.50
Huile de vaseline 5,00Vaseline oil 5.00
Huile d'amandes douces 2,00Sweet almond oil 2.00
Huile de chaulmoogra 10,00Chaulmoogra oil 10.00
Alcool cétostéarylique 1,00 Phényl diméthicone 2,00Cetostearyl alcohol 1.00 Phenyl dimethicone 2.00
Tocophérol 0,70 Phase B Tocopherol 0.70 Phase B
Oxyde de zinc et triglycérides caprique  Zinc oxide and capric triglycerides
/ caprylique et Paraffinum liquidum et  / caprylic and Paraffinum liquidum and
acide polyhydroxystéarique 10,00 Phase C  polyhydroxystearic acid 10.00 Phase C
Gomme xanthane 0,50 Xanthan Gum 0.50
Pentylène glycol 4,00Pentylene glycol 4.00
Ethyl hexyl glycérine 0,30 Acide anisique 0,10Ethyl hexyl glycerin 0.30 Anisic acid 0.10
Acide lévulinique 0,20Levulinic acid 0.20
Oxyde de zinc et Eau et Silice et PEG 2M 5,00Zinc Oxide and Water and Silica and PEG 2M 5.00
Eau déminéralisée q.s.p. 100,00Demineralized water q.s. 100.00
Extrait de Tribulus terrestris 0,10 Phase D Tribulus terrestris extract 0.10 Phase D
Parfum 0,50 Perfume 0,50
La phase grasse A est chauffée sous agitation à environ 75°C et on y ajoute la phase grasse B puis la phase aqueuse C à environ 75°C, et les trois phases sont mélangées soigneuse- ment sous agitation. Enfin, on ajoute la phase D et l'ensemble est ensuite mélangé et refroidi progressivement. Fat phase A is heated with stirring to about 75 ° C and fat phase B is added thereto and then aqueous phase C at about 75 ° C, and the three phases are thoroughly mixed. with stirring. Finally, phase D is added and the mixture is then mixed and cooled progressively.
Cette crème peut être utilisée par application sur les zones dépigmentées de la peau à traiter, une à deux fois par jour, pendant une période de un à trois mois. Des résultats positifs sont observés dans certains cas, notamment lors du traitement d'une zone atteinte par un vitiligo, dès la fin de la 4ème semaine d'application. Si le traitement est arrêté après 1 mois, on observe une régression de la pigmentation générale mais les zones repigmentées restent acquises.  This cream can be used per application on the depigmented areas of the skin to be treated, once or twice a day, for a period of one to three months. Positive results are observed in some cases, especially when treating an area affected by vitiligo, from the end of the 4th week of application. If the treatment is stopped after 1 month, there is a regression of the general pigmentation but the repigmented areas remain acquired.
Exemple 3 Example 3
Evaluation de la cytotoxicité  Evaluation of cytotoxicity
La cytotoxicité de l'association d'extrait de Tribulus terrestris et d'huile de chaulmoogra a été évaluée par étude de mélanocytes humains en culture, comme suit.  The cytotoxicity of the combination of Tribulus terrestris extract and chaulmoogra oil was evaluated by studying human melanocytes in culture, as follows.
Pour constituer des épidermes, des kératinocytes d'origine humaine sont ensemencés sur des filtres en polycarbonate de 0,5 cm2 dans un milieu défini (MCDB 153 modifié) et supplémenté. Les cellules sont cultivées pendant 14 jours à l'interface air/liquide, le milieu de culture étant changé tous les deux jours. To constitute epidermals, keratinocytes of human origin are seeded on polycarbonate filters of 0.5 cm 2 in a defined medium (modified MCDB 153) and supplemented. The cells are cultured for 14 days at the air / liquid interface, the culture medium being changed every two days.
Les épidermes ainsi formés (Skinetic®) sont utilisés pour l'étude à partir du i4eme jour de culture. The thus formed epidermis (SKINETIC®) are used for the study from the i4 th day of culture.
Des mélanocytes humains ont été établis à partir de peau humaine (Clonetics) et amplifiés dans du milieu MGM (Melanocytes Growth Médium, Clonetics) . Les essais ont été réalisés sur des mélanocytes entre le 2eme et le 4eme passage afin d'assurer une reproductibilité entre les différentes expérimentations . Human melanocytes were established from human skin (Clonetics) and amplified in MGM medium (Melanocytes Growth Medium, Clonetics). The tests were carried out on melanocytes between the 2 nd and 4 th passage to ensure reproducibility between different experiments.
La cytotoxicité a été évaluée pour la co-culture mélanocytes humains / épidermes reconstitués, par déter¬ mination de la viabilité cellulaire par le test de réduction au bleu de Formazan (MTT) . Les mélanocytes ont été répartis dans des plaques 24 puits à raison de 2xl05 cellules par puit dans 0,5 ml de milieu de culture pendant 12 heures. Les épidermes traités et non traités ont été ensuite déposés dans les puits contenant les mélanocytes en culture. Cytotoxicity was assessed for co-culture human melanocytes / reconstructed epidermis, for deter ¬ mination of cell viability by the reduction of formazan blue test (MTT). The melanocytes were distributed in 24-well plates at a rate of 2 × 10 5 cells per well in 0.5 ml of culture medium for 12 hours. The treated and untreated epidermis was then deposited in the wells containing the melanocytes in culture.
L'essai a été conduit après 24 heures de contact entre le produit étudié et la co-culture mélanocytes / épidermes reconstitués .  The test was conducted after 24 hours of contact between the studied product and the reconstituted melanocyte / epidermal co-culture.
Deux lots de co-cultures ont été constitués pour les tests.  Two batches of co-cultures were set up for the tests.
Lot 1 : co-culture témoin négatif ne recevant aucun produit .  Lot 1: negative control co-culture receiving no product.
Lot 2 : co-culture traitée par l'association huile de chaulmoogra (5%) / Tribulus terrestris (0,1%).  Lot 2: co-cultivation treated by the combination of chaulmoogra oil (5%) / Tribulus terrestris (0.1%).
La viabilité des mélanocytes est évaluée comme suit.  The viability of melanocytes is evaluated as follows.
Après 24 heures d'incubation de la co-culture, la viabilité cellulaire a été déterminée par le test de réduction au bleu de Formazan (test MTT) . Après incubation des cellules de chaque lot, les épidermes sont récupérés et les puits contenant les cellules sont vidés par retournement et le tapis cellulaire est rincé avec le milieu de culture, 200 μΐ d'une solution de MTT (bromure de 3- ( 4 , 5-diméthylthiazol-2-yl ) -2 , 5- diphényltétrazolium) à 5 mg/ml, sont distribués dans tous les puits. Les plaques sont incubées à 37°C pendant 3 heures. Les puits sont à nouveau vidés par retournement, et le tapis cellulaire est fixé pendant 1 minute par 200 μΐ de solution de formo-calcium. Les cellules sont ensuite lysées et les cristaux de bleu de Formazan sont dissous par 200 μΐ de diméthylsulfoxyde . La densité optique (DO) des plaques est lue, après homogénéisation de la coloration par agitation, au moyen d'un spectrophotomètre réglé à 570 nm, permettant ainsi de connaître la quantité relative de cellules vivantes et actives métaboliquement .  After 24 hours of co-culture incubation, cell viability was determined by the Formazan blue reduction test (MTT test). After incubation of the cells of each batch, the epidermis are recovered and the wells containing the cells are emptied by inversion and the cell layer is rinsed with the culture medium, 200 μl of a solution of MTT (bromide of 3- (4, 5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium) 5 mg / ml are distributed in all wells. The plates are incubated at 37 ° C for 3 hours. The wells are again emptied by inversion, and the cellular mat is fixed for 1 minute with 200 μl of formo-calcium solution. The cells are then lysed and the Formazan blue crystals are dissolved with 200 μl of dimethylsulfoxide. The optical density (OD) of the plates is read, after homogenization of the staining by stirring, using a spectrophotometer set at 570 nm, thus making it possible to know the relative quantity of living and metabolically active cells.
La viabilité cellulaire des épidermes a été évaluée comme suit. Les épidermes reconstitués ont été mis individuellement en contact avec 150 μΐ de MTT, puis mis dans l'incubateur pendant 1 heure. A la fin de l'incubation, les épidermes sont récupérés. Les cellules sont ensuite lysées et les cristaux de bleu de Formazan dissous, puis 200 μΐ de diméthyl sulfoxyde sont ajoutés. Après homogénéisation de la coloration par agitation, les plaques sont lues par un spectrophotomètre réglé à 570 nm. The cell viability of the epidermis was evaluated as follows. The reconstituted epidermis was individually contacted with 150 μl of MTT and placed in the incubator for 1 hour. At the end of the incubation, the epidermis are recovered. The cells are then lysed and the crystals of Formazan blue dissolved, then 200 μl of dimethyl sulfoxide are added. After homogenization of the coloration by stirring, the plates are read by a spectrophotometer set at 570 nm.
Les résultats sont regroupés dans les tableaux ci-après. Epidermes reconstitués :  The results are summarized in the tables below. Reconstituted Epiderms:
Figure imgf000020_0001
Figure imgf000020_0001
Ces résultats montrent que l'association suivant l'invention ne présente aucune cytotoxicité vis-à-vis des épidermes reconstitués. These results show that the combination according to the invention shows no cytotoxicity with respect to the reconstituted epidermis.
Exemple 4 Example 4
Evaluation de l'effet sur la pigmentation L'effet pigmentant a été étudié à travers  Evaluation of the effect on pigmentation The pigmenting effect was studied through
· l'évaluation de la capture de la [3H] L-tyrosine · Evaluation of the capture of [3 H] L-tyrosine
• l'évaluation de la capture de [14C] L-phénylalanine • evaluation of [ 14 C] L-phenylalanine uptake
• l'évaluation de la synthèse de la [14C] tyrosine • evaluation of the synthesis of [ 14 C] tyrosine
• l'évaluation de l'activité de la tyrosinase  • evaluation of tyrosinase activity
L'étude a été faite sur les mêmes lots que dans l'Exemple 3 ci-dessus. L'essai est conduit en triplicate après 3 jours de contact . The study was done on the same batches as in Example 3 above. The test is conducted in triplicate after 3 days of contact.
Evaluation de la capture de la L-tyrosine :  Evaluation of the capture of L-tyrosine:
L'évaluation de la capture de la [3H] L-tyrosine a été effectuée comme indiqué ci-après. The evaluation of the [ 3 H] L-tyrosine uptake was carried out as indicated below.
La capacité des cellules préalablement traitées par les produits à l'étude à capturer les précurseurs radioactifs a été évaluée par la méthode de puise. Les précurseurs radioactifs sont ajoutés aux cultures après incubation avec l'association de l'invention. Les cellules sont alors incubées pendant 20 minutes à 37°C en présence de [3H] L-tyrosine (130 pmol., activité spécifique 47 Ci/mmol.). The ability of the cells previously treated by the products under study to capture the radioactive precursors was evaluated by the method of withdrawal. The radioactive precursors are added to the cultures after incubation with the combination of the invention. The cells are then incubated for 20 minutes at 37 ° C. in the presence of [ 3 H] L-tyrosine (130 pmol., Specific activity 47 Ci / mmol).
Le milieu est éliminé par aspiration, puis les cellules sont lavées 3 fois avec du milieu sans sérum pour éliminer la radioactivité, puis détachées du support et lavées à nouveau avec du milieu et enfin centrifugées à 600 g pendant 5 minutes. Le culot cellulaire est repris par 500 μΐ de milieu. Pour déterminer la radioactivité incorporée dans les mélanocytes, les cellules sont soniquées puis introduites dans des flacons de comptage. La radioactivité est mesurée dans un compteur à scintillation ne présence de 5 ml de liquide de scintillation (Ready organique, Beckman) contenant 0,9% d'acide acétique.  The medium is removed by aspiration, then the cells are washed 3 times with serum-free medium to remove the radioactivity, then detached from the support and washed again with medium and finally centrifuged at 600 g for 5 minutes. The cell pellet is taken up in 500 μΐ of medium. To determine the radioactivity incorporated in the melanocytes, the cells are sonicated and then introduced into counting flasks. The radioactivity is measured in a scintillation counter with the presence of 5 ml of scintillation fluid (organic Ready, Beckman) containing 0.9% acetic acid.
Les résultats sont regroupés dans le tableau ci-après.  The results are summarized in the table below.
Figure imgf000021_0001
Figure imgf000021_0001
Ces résultats montrent que l'irradiation des mélanocytes par des rayons ultraviolets B augmente significativement (44%) la capture de la [3H] L-tyrosine. En l'absence d'irradiation, l'association de l'invention induit un effet significatif en comparaison du témoin négatif sur la capture de la [3H] L- tyrosine . These results show that the irradiation of melanocytes with ultraviolet B rays significantly increases (44%) the capture of [ 3 H] L-tyrosine. In the absence of irradiation, the combination of the invention induces a significant effect compared to the negative control on the capture of [ 3 H] L-tyrosine.
Evaluation de la capture de la L-phénylalanine :  Evaluation of the capture of L-phenylalanine:
La même méthode que ci-dessus a été utilisée en remplaçant la [ H] L-tyrosme par la [ C] L-phenylalanme (130 pmol., activité spécifique 474 mCi/mmol.).  The same method as above was used replacing the [H] L-tyrosine with [C] L-phenylalanine (130 pmol, specific activity 474 mCi / mmol.).
Les résultats sont regroupés dans le tableau ci-après.  The results are summarized in the table below.
Figure imgf000022_0001
Ces résultats montrent que l'irradiation de la co-culture par des rayons ultraviolets B augmente significativement (40%) la capture de la [14C] L-phénylalanine. En l'absence d'irra¬ diation, l'association de l'invention induit un effet significatif (18%) en comparaison du témoin négatif.
Figure imgf000022_0001
These results show that the irradiation of the co-culture with ultraviolet B rays significantly increases (40%) the capture of [ 14 C] L-phenylalanine. In the absence of irra diation ¬, the combination of the invention induced a significant (18%) compared to the negative control.
Evaluation de la synthèse de la L-tyrosine : Evaluation of the synthesis of L-tyrosine:
La néosynthèse de la [14C] L-tyrosine a été évaluée par incorporation de la [14C] L-phénylalanine dans les mélanocytes humains en culture. Une fois capturée, la phénylalanine se transforme en effet en tyrosine, ce qui aboutit à la synthèse de la mélanine. The [ 14 C] L-tyrosine neosynthesis was evaluated by incorporation of [ 14 C] L-phenylalanine into human melanocytes in culture. Once captured, the phenylalanine is converted into a tyrosine effect, which results in the synthesis of melanin.
La transformation de [14C] L-phénylalanine en [14C] L- tyrosine est étudiée sur une durée de 20 minutes. La capture et la transformation de la phénylalanine est suivie après addition de 130 pmol de L-phénylalanine aux mélanocytes en monocouche . The transformation of [ 14 C] L-phenylalanine into [ 14 C] L-tyrosine is studied over a period of 20 minutes. The capture and transformation of phenylalanine is monitored after addition of 130 pmol of L-phenylalanine to melanocytes in monolayer.
Le milieu est éliminé et les cellules sont lavées trois fois avec Tris/HCl (0,05 M, pH 7,5) puis digérées avec de la trypsine (1 mg/ml) . La [14C] L-tyrosine et la [14C] L-phényl- alanine sont étudiée par HPLC avec un éluant chloroforme / méthanol / eau / hydroxyde d'ammonium (29:15:1:4 v/v). The medium is removed and the cells are washed three times with Tris / HCl (0.05 M, pH 7.5) and then digested with trypsin (1 mg / ml). [ 14 C] L-tyrosine and [ 14 C] L-phenylalanine are studied by HPLC with a chloroform / methanol / water / ammonium hydroxide eluent (29: 15: 1: 4 v / v).
Les résultats sont regroupés dans le tableau ci-après.  The results are summarized in the table below.
Figure imgf000023_0001
Figure imgf000023_0001
Ces résultats montrent que l'irradiation des mélanocytes par des rayons ultraviolets B augmente significativement (35%) la synthèse de la [14C] L-tyrosine. En l'absence d'irra¬ diation, l'association de l'invention induit un effet significatif (19%) en comparaison du témoin négatif. These results show that the irradiation of melanocytes with ultraviolet B rays significantly increases (35%) the synthesis of [ 14 C] L-tyrosine. In the absence of irra diation ¬, the combination of the invention induced a significant (19%) compared to the negative control.
Evaluation de l'activité de la L-tyrosinase :  Evaluation of the activity of L-tyrosinase:
En fin d'incubation, le milieu de culture est prélevé puis les cellules sont rincées avec du PBS et mis au contact du Triton X-100 (Sima, France) à 1%, puis incubées pendant 10 minutes. La réaction enzymatique est initiée par addition de L-dopamine (Sigma, France) à 10 mM dans du PBS dépourvu de Ca2+ et de Mg2+. At the end of incubation, the culture medium is removed and the cells are then rinsed with PBS and placed in contact with Triton X-100 (Sima, France) at 1%, and then incubated for 10 minutes. The enzymatic reaction is initiated by addition of L-dopamine (Sigma, France) to 10 mM in PBS devoid of Ca 2+ and Mg 2+ .
Après une heure d'incubation à 37°C à l'abri de la lumière, l'activité de la tyrosinase est évaluée par mesure de l'absorption à 475 nm à l'aide d'un spectrophotomètre .  After one hour of incubation at 37 ° C, protected from light, the tyrosinase activity is evaluated by measuring the absorption at 475 nm using a spectrophotometer.
Les résultats sont regroupés dans le tableau ci-après.  The results are summarized in the table below.
Activité de la tyrosinase % Tyrosinase activity%
Témoin 100 Witness 100
Témoin positif UVB 100mJ/cm2 172 Positive control UVB 100mJ / cm 2 172
T. terrestris 0,1% + huile de 120  T. terrestris 0.1% + oil of 120
chaulmoogra 5%  chaulmoogra 5%
T. terrestris 0,1% + huile de 175  T. terrestris 0.1% + 175 oil
chaulmoogra 5% UVB 100mJ/cm2 Ces résultats montrent que l'irradiation de la co-culture par des rayons ultraviolets B augmente significativement l'activité de la tyrosinase. En l'absence d'irradiation, l'association de l'invention induit un effet significatif en comparaison du témoin négatif. chaulmoogra 5% UVB 100mJ / cm 2 These results show that the irradiation of co-culture with ultraviolet B rays significantly increases the activity of tyrosinase. In the absence of irradiation, the combination of the invention induces a significant effect compared to the negative control.
Ces résultats confirment que l'association de Tribulus terrestris et d'huile de chaulmoogra de l'invention joue un rôle pigmentant significatif dans toutes les étapes du processus de pigmentation. Exemple 5 (comparatif)  These results confirm that the combination of Tribulus terrestris and chaulmoogra oil of the invention plays a significant pigmenting role in all stages of the pigmentation process. Example 5 (comparative)
Evaluation de l'effet dépigmentant de Tribulus terrestris La cytotoxicité a été vérifiée par évaluation de la viabilité cellulaire sur des mélanocytes humains comme dans l'exemple 4 ci-dessus.  Evaluation of the Depigmenting Effect of Tribulus Terrestris Cytotoxicity was verified by evaluation of cell viability on human melanocytes as in Example 4 above.
L'étude montre que l'extrait de Tribulus terrestris, aux concentrations de 0,05% et 0,1%, ne présente aucune cyto¬ toxicité. L'extrait se révèle cytotoxique à partir de 0,2%. The study shows that the extract of Tribulus terrestris, at concentrations of 0.05% and 0.1%, exhibits no cyto ¬ toxicity. The extract is cytotoxic from 0.2%.
Quatre lots ont été constitués pour montrer l'effet de Tribulus terrestris sur des co-cultures épidermes / mélano- cytes.  Four batches were constructed to show the effect of Tribulus terrestris on epidermal / melanocyte co-cultures.
Lot 1 : co-culture témoin négatif ne recevant aucun produit .  Lot 1: negative control co-culture receiving no product.
Lot 2 : co-culture témoin positif recevant de l'acide ko ique (2%) .  Lot 2: positive control co-culture receiving koic acid (2%).
Lot 3 : co-culture traitée Tribulus terrestris (0,05%). Lot 3: treated coculture Tribulus terrestris (0.05%).
Lot 4 : co-culture traitée Tribulus terrestris (0,1%). L'effet sur la pigmentation a été étudié par l'évaluation de l'activité de la tyrosinase et par l'évaluation de la synthèse de la mélanine. Lot 4: co-cultivation treated Tribulus terrestris (0.1%). The effect on pigmentation was studied by evaluating the activity of tyrosinase and by evaluating the synthesis of melanin.
L'évaluation de la synthèse de la mélanine intracellu¬ laire est effectuée par spectrophotométrie à 475 nm après mise en suspension puis dissolution des cellules dans NaOH (IN) et du diméthyl suifoxyde pendant 30 minutes. Les résultats sont regroupés dans le tableau ci-après. The evaluation of the synthesis of melanin intracellu ¬ lar is carried out by spectrophotometry at 475 nm after suspending and dissolving the cells in NaOH (IN) and dimethyl sulfoxide for 30 minutes. The results are summarized in the table below.
Figure imgf000025_0001
Figure imgf000025_0001
Ces résultats montrent que l'extrait de Tribulus terrestris, aux concentrations testées, entraîne une diminu¬ tion significative du taux de mélanine comparable au témoin positif recevant l'acide kojique à 2%, dépigmentant connu. These results show that the extract of Tribulus terrestris, at the concentrations tested, results in a significant decreased ¬ tion of melanin levels comparable to the positive control receiving the 2% kojic acid known depigmenting agent.
L'évaluation de l'activité de la tyrosinase est effectuée comme dans l'Exemple 4 ci-dessus.  The evaluation of tyrosinase activity is performed as in Example 4 above.
Les résultats sont regroupés dans le tableau ci-après.  The results are summarized in the table below.
Figure imgf000025_0002
Figure imgf000025_0002
Ces résultats montrent que l'extrait de Tribulus terrestris entraîne une diminution significative de l'activité de la tyrosinase comparable à celle de l'acide kojique. These results show that Tribulus terrestris extract leads to a significant decrease in tyrosinase activity comparable to that of kojic acid.
L'ensemble de ces résultats montre que l'extrait de Tribulus terrestris, utilisé isolément, a une activité dépigmentante significative, bien que faible.  All of these results show that tribulus terrestris extract, used alone, has a significant, although weak, depigmenting activity.

Claims

REVENDICATIONS
1. Composition cosmétique pour la pigmentation de la peau, comprenant de l'huile de chaulmoogra et /ou ses composants et un extrait de Tribulus terrestris dans un rapport en poids Tribulus terrestris / huile de chaulmoogra compris entre 1:1.000 et 1:5. A cosmetic composition for skin pigmentation, comprising chaulmoogra oil and / or its components and an extract of Tribulus terrestris in a weight ratio Tribulus terrestris / chaulmoogra oil of between 1: 1,000 and 1: 5.
3. Composition selon la revendication 1, caractérisée en ce que les composants de l'huile de chaulmoogra sont les acides chaulmoogrique, hydnocarpique et gorlique, ainsi que leurs sels et esters.  3. Composition according to claim 1, characterized in that the components of the oil of chaulmoogra are chaulmoogric, hydnocarpic and gorlic acids, as well as their salts and esters.
3. Composition selon la revendication 2, caractérisée en ce qu'elle comprend les sels ou esters des acides chaulmoogrique, hydnocarpique et gorlique.  3. Composition according to claim 2, characterized in that it comprises the salts or esters of chaulmoogric, hydnocarpic and gorlic acids.
4. Composition selon la revendication 3, caractérisée en ce que les sels et esters sont choisis parmi les esters de méthyle, d'éthyle ou de benzyle, ainsi que les sels de sodium ou de potassium.  4. Composition according to Claim 3, characterized in that the salts and esters are chosen from methyl, ethyl or benzyl esters, as well as sodium or potassium salts.
5. Composition selon l'une quelconque des revendica¬ tions précédentes, caractérisée en ce que la teneur en huile de chaulmoogra, ou en acides ou sels ou esters est comprise entre 0,1 et 20% en poids par rapport au poids total de la composition . 5. Composition according to any one of the preceding revendica ¬ tions, characterized in that the oil content of chaulmoogra, or acids or salts or esters is between 0.1 and 20% by weight relative to the total weight of the composition.
6. Composition selon la revendication 5, caractérisée en ce que la teneur en huile de chaulmoogra, ou en acides ou sels ou esters est comprise entre 2 et 10% en poids par rapport au poids total de la composition.  6. Composition according to claim 5, characterized in that the oil content of chaulmoogra, or acids or salts or esters is between 2 and 10% by weight relative to the total weight of the composition.
7. Composition selon la revendication 1, caractérisée en ce que l'extrait de Tribulus terrestris est obtenu à partir de graines ou fruits préalablement séchés et broyés.  7. Composition according to claim 1, characterized in that the extract of Tribulus terrestris is obtained from seeds or fruits previously dried and crushed.
8. Composition selon la revendication 7, caractérisée en ce que l'extrait de Tribulus terrestris est un extrait hydroglycolique .  8. Composition according to claim 7, characterized in that the tribulus terrestris extract is a hydroglycolic extract.
9. Composition selon la revendication 1, caractérisée en ce que la teneur en extrait de Tribulus terrestris est comprise entre 0,01 et 0,5% en poids par rapport au poids total de la composition. 9. Composition according to claim 1, characterized in that the extract content of Tribulus terrestris is between 0.01 and 0.5% by weight relative to the total weight of the composition.
10. Composition selon l'une quelconque des revendi¬ cations précédentes, caractérisée en ce que le rapport en poids de l'extrait de Tribulus terrestris à l'huile de chaulmoogra dans la composition est compris entre 1:200 et 1:20. 10. Composition according to any one of the preceding revendi ¬ cations, characterized in that the weight ratio of the tribulus terrestris extract to the oil of chaulmoogra in the composition is between 1: 200 and 1:20.
11. Composition selon l'une quelconque des revendi¬ cations précédentes, caractérisée en ce que la teneur en huile de chaulmoogra, ou en acides ou sels ou esters est comprise entre 2 et 10% en poids, et la teneur en extrait de Tribulus terrestris est comprise entre 0,05 et 0,2% en poids par rapport au poids total de la composition. 11. Composition according to any one of the preceding revendi ¬ cations, characterized in that the oil content of chaulmoogra, or acids or salts or esters is between 2 and 10% by weight, and the extract content of Tribulus terrestris is between 0.05 and 0.2% by weight relative to the total weight of the composition.
12. Procédé de traitement cosmétique de la peau, pour la pigmentation de zones dépigmentées ou non pigmentées, par application d'une composition à base d'huile de chaulmoogra et d'extrait de Tribulus terrestris sur la zone de la peau nécessitant un tel traitement.  12. Process for the cosmetic treatment of the skin, for the pigmentation of depigmented or non-pigmented areas, by application of a composition based on chaulmoogra oil and Tribulus terrestris extract on the area of the skin requiring such treatment .
PCT/FR2012/050723 2011-04-05 2012-04-03 Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation WO2012136930A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12718295.4A EP2694028A2 (en) 2011-04-05 2012-04-03 Composition based on chaulmoogra oil and tribulus terrestris for skin pigmentation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1152925 2011-04-05
FR1152925A FR2973697B1 (en) 2011-04-05 2011-04-05 COMPOSITION BASED ON OIL OF CHAULMOOGRA AND TRIBULUS TERRESTRIS FOR THE PIGMENTATION OF THE SKIN.

Publications (2)

Publication Number Publication Date
WO2012136930A2 true WO2012136930A2 (en) 2012-10-11
WO2012136930A3 WO2012136930A3 (en) 2013-10-17

Family

ID=46025781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2012/050723 WO2012136930A2 (en) 2011-04-05 2012-04-03 Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation

Country Status (3)

Country Link
EP (1) EP2694028A2 (en)
FR (1) FR2973697B1 (en)
WO (1) WO2012136930A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3056906A1 (en) * 2016-10-05 2018-04-06 Patrick Terentieff REPIGMENTANT SPECIAL MILK FOR MATURE, METISSEES AND BLACK SKINS

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518402A1 (en) 1981-12-21 1983-06-24 Sederma Sa Cosmetic compsn. contg. chaulmoogra oil - used partic. for treating skin trouble, e.g. acne, and also in hair care and make up compsns.
FR2654935A1 (en) 1989-11-28 1991-05-31 Lvmh Rech USE OF XANTHINES, POSSIBLY INCORPORATED IN LIPOSOMES, TO PROMOTE THE PIGMENTATION OF SKIN OR HAIR.
FR2706304A1 (en) 1993-06-15 1994-12-23 Carita Sa Use of Chaulmoogra oils in the cosmetic and pharmaceutical field, especially in dermatology, to harmonize the pigmentation of the skin.
WO1999051198A1 (en) 1998-04-06 1999-10-14 Codon Pharmaceuticals, Inc. Dermatological formulations and methods
EP0993826A1 (en) 1998-09-07 2000-04-19 L'oreal Use of a sanguisorba officinalis extract to stimulate the skin- and/or the hair-pigmentation
WO2003082227A1 (en) 2002-03-29 2003-10-09 Sakamoto Bio Co., Ltd. Melanogenesis regulator
FR2851916A1 (en) 2003-03-05 2004-09-10 Oreal Use of at least one catechu polyphenol in a composition aiding natural pigmentation of the skin or skin eruptions or lesions useful for increasing the perfusion of cutaneous blood, and for prevention or diminishing of canities
FR2876908A1 (en) 2004-10-22 2006-04-28 Nuxe Sa Lab Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis
CN101406511A (en) 2008-11-18 2009-04-15 蒋保珍 External-use medicament for treating vitiligo
KR20090056778A (en) 2007-11-29 2009-06-03 김진홍 Composition comprising the crude extract for preventing and treating allergic skin diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675966A (en) * 2008-09-19 2010-03-24 郭晓宇 Medicament for treating psoriasis
CN101721662A (en) * 2008-11-04 2010-06-09 张宝国 Bone-strengthening blood-stasis-dissipating plaster
CN101953927B (en) * 2010-08-27 2011-11-23 张丽君 External Chinese medicinal liniment for treating urticaria

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518402A1 (en) 1981-12-21 1983-06-24 Sederma Sa Cosmetic compsn. contg. chaulmoogra oil - used partic. for treating skin trouble, e.g. acne, and also in hair care and make up compsns.
FR2654935A1 (en) 1989-11-28 1991-05-31 Lvmh Rech USE OF XANTHINES, POSSIBLY INCORPORATED IN LIPOSOMES, TO PROMOTE THE PIGMENTATION OF SKIN OR HAIR.
FR2706304A1 (en) 1993-06-15 1994-12-23 Carita Sa Use of Chaulmoogra oils in the cosmetic and pharmaceutical field, especially in dermatology, to harmonize the pigmentation of the skin.
WO1999051198A1 (en) 1998-04-06 1999-10-14 Codon Pharmaceuticals, Inc. Dermatological formulations and methods
EP0993826A1 (en) 1998-09-07 2000-04-19 L'oreal Use of a sanguisorba officinalis extract to stimulate the skin- and/or the hair-pigmentation
WO2003082227A1 (en) 2002-03-29 2003-10-09 Sakamoto Bio Co., Ltd. Melanogenesis regulator
FR2851916A1 (en) 2003-03-05 2004-09-10 Oreal Use of at least one catechu polyphenol in a composition aiding natural pigmentation of the skin or skin eruptions or lesions useful for increasing the perfusion of cutaneous blood, and for prevention or diminishing of canities
FR2876908A1 (en) 2004-10-22 2006-04-28 Nuxe Sa Lab Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis
KR20090056778A (en) 2007-11-29 2009-06-03 김진홍 Composition comprising the crude extract for preventing and treating allergic skin diseases
CN101406511A (en) 2008-11-18 2009-04-15 蒋保珍 External-use medicament for treating vitiligo

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. GAUTHAMAN, PHYTOMEDICINE, vol. 15, 2008, pages 44 - 54
M.R. ASLANI ET AL., VET. RES. COMMUN., vol. 27, 2003, pages 53 - 62
P.L. JACOBSEN; L. LEVY, ANTIMYCOBACTERIAL AGENTS AND CHEMOTHERAPY, 1973, pages 373 - 379

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3056906A1 (en) * 2016-10-05 2018-04-06 Patrick Terentieff REPIGMENTANT SPECIAL MILK FOR MATURE, METISSEES AND BLACK SKINS

Also Published As

Publication number Publication date
WO2012136930A3 (en) 2013-10-17
FR2973697A1 (en) 2012-10-12
FR2973697B1 (en) 2013-10-25
EP2694028A2 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
EP1879602B1 (en) Use of cacao polyphenols for controlling skin pigmentation
EP2691074A1 (en) Composition based on camellia japonica and polygonum hydropiper for protecting the skin
EP1786384A1 (en) Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation
WO1990006104A1 (en) Use of kaempferol and certain derivatives thereof for the preparation of a cosmetic or pharmaceutical composition
WO2009141543A1 (en) Use of a berry extract, especially a wolfberry extract, as an anti-pollutant
WO2009122046A1 (en) Crocus sativus depigmenting composition
EP1877034B1 (en) Use of cocoa polyphenols for cell cycle regulation in the treatment of hyperkeratinisation
EP1811953B1 (en) Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics
WO2012136930A2 (en) Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation
EP2699227B1 (en) Plant extract complex for skin protection
EP2811978B1 (en) Use of an apple tree bark extract in a cosmetic anti-ageing composition
EP2046356A2 (en) Use of an extract of gleditsia in cosmetics and in dermatology
EP2811977B1 (en) Use of an apple tree leaf extract in a cosmetic skin-firming composition
FR2859102A1 (en) USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC
FR2876909A1 (en) Cosmetic and/or pharmaceutical composition, to prevent or treat adipose overloads and cellulitis, comprises a combination of one or more xanthinic bases and chaulmoogra oil and/or its components
FR2885300A1 (en) Topical cosmetic and/or dermatological composition useful for skin protection comprises an araucaria seed extract
FR2876908A1 (en) Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis
FR3021539A1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION COMPRISING A VEGETABLE EXTRACT AND A GENE ACTIVATOR
WO2006117464A1 (en) Skin protective composition based on araucaria grain extracts
WO2012172200A1 (en) Composition based on samanea saman for protecting the skin
FR2885049A1 (en) Topical cosmetic and/or dermatological composition, useful to protect the skin and to fight against the climatic and environmental effect, comprises a seed extract of Araucaria
FR2986707A1 (en) COMPOSITION COMPRISING APPLE JUICE EXTRACT FOR SKIN COMFORT.
WO2012140352A2 (en) Gleditsia composition for treating excess fat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12718295

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2012718295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012718295

Country of ref document: EP